← 產業報告目錄

Nucleic Acid Isolation and Purification Market by Product (Kits, Reagents, Instruments), Method (Column, Magnetic Beads), Type (Genomic DNA, Plasmid DNA), Application (Diagnostics, Personalized Medicine), End User (CROs), Region - Global Forecast to 2030

出版商 MarketsandMarkets產業別 Healthcare & Life Sciences出版日期 2026-01-20頁數 545報告編號 BT2398

授權報價

Single User Licence$4,950 USD
Multi User Licence$6,650 USD
Corporate User Licence$8,150 USD
Global User Licence$10,000 USD
洽詢購買 申請 Sample

報告摘要

The nucleic acid isolation and purification market is expected to grow from USD 7.10 billion in 2025 to USD 10.99 billion in 2030, at a CAGR of 9.1% during the forecast period. PCR and other NAAT workflows are routine in many infectious disease programs. Labs are expanding test menus and handling higher sample volumes. NGS is also moving deeper into clinical use cases, increasing the need for clean DNA/RNA as a first step. Declining extraction quality affects downstream sensitivity. This encourages end users to continue investing in reliable NAIP workflows and reagents. “The magnetic-bead based isolation and purification segment accounted for the largest share, by method, in the nucleic acid isolation and purification market in 2024.” The nucleic acid isolation and purification market is segmented into magnetic bead-based isolation and purification, column-based isolation and purification, reagent-based isolation and purification, and other methods. In 2024, the magnetic bead-based isolation and purification method dominated the market. This dominance is driven by the compatibility of bead workflows with automation and high-throughput processing, which are priorities for hospitals, reference labs, and large research centers. Bead-based methods also deliver consistent yields and reproducibility across batches, helping labs reduce reruns and maintain turnaround times.   “The diagnostics segment was the largest application segment in the nucleic acid isolation and purification market in 2024.” The nucleic acid isolation and purification market is segmented by application into diagnostics, drug discovery & development, personalized medicine, agriculture & animal research, and other applications. The diagnostics segment led the market in 2024. The primary reason is that DNA/RNA extraction is a necessary first step for most PCR/NAAT assays. In addition, a growing number of sequencing-based clinical tests is supporting expansion. High routine volumes from infectious disease panels, respiratory testing, and oncology molecular assays maintain steady demand. Diagnostic labs also prioritize standardized and validated workflows to reduce variability, avoid reruns, and shorten turnaround times. “The Asia Pacific region will grow at the highest CAGR in the nucleic acid isolation and purification market from 2025 to 2030.” The Asia Pacific region is estimated to be the fastest-growing segment of the market. This growth is supported by the expansion of population genomics programs and the rising focus on precision medicine. The region is also seeing increased demand for diagnosis and monitoring of rare and genetic diseases, especially in aging populations in markets such as Japan and China. As a result, sequencing and other molecular testing are being adopted more widely in routine healthcare. The primary interviews conducted for this report can be categorized as follows: • By Company Type: Tier 1- 40%, Tier 2- 30% and Tier 3- 30% • By Designation: Directors- 20%, Managers- 10% and Others - 70%, • By Region: North America -35%, Europe -25%, Asia Pacific -25%, Latin America -10%, and Middle East -5%. List of Companies Profiled in the Report: • Thermo Fisher Scientific Inc. (US) • Merck KGaA (Germany) • QIAGEN (Germany) • F. Hoffmann-La Roche Ltd. (Switzerland) • Promega Corporation (US) • Agilent Technologies, Inc. (US) • Danaher(US) • Bio-Rad Laboratories, Inc. (US) • Illumina, Inc. (US) • Takara Bio Inc. (Japan) • New England Biolabs (US) • Abcam Plc (UK) • KILPEST India Limited (India) • Apical Scientific Sdn. Bhd. (Malaysia) • Endress+Hauser Group Services AG (Switzerland) • GENAXXON bioscience GmbH (Germany) • LGC Biosearch Technologies (US) • Zymo Research Corporation (US) • Norgen Biotek Corp. (Canada) • Omega Bio-Tek, Inc. (US) • FAVORGEN Biotech Corp. (China) • TIANGEN Biotech (Beijing) Co., Ltd. (China) • AutoGen Inc. (US) • PCR Biosystems (UK) • Biogenuix (India) Research Coverage This research report categorizes the nucleic acid isolation and purification market by product [Kits, Reagents, Instruments (Manual, Automatic)], by type (Plasmid DNA isolation and purification, Total RNA isolation and purification, Genomic DNA isolation and purification, Messenger RNA isolation and purification, Circulating nucleic acid isolation and purification, MicroRNA isolation and purification, Other types), by method (Magnetic bead-based isolation and purification, Reagent-based isolation and purification, Column-based isolation and purification, Other methods), by application (Diagnostics, Drug discovery & development, Personalized medicine, Agriculture and animal research, Other applications), by end user (Hospitals and diagnostic centers, Academic and government research institutes, Pharmaceutical and biotechnology companies, Contract Research Organizations (CROs), Other end users), and by region (North America, Europe, Asia Pacific, Latin America, Middle East, and Africa). The scope of the report covers detailed information on the major factors, such as drivers, challenges, opportunities, and restraints, that influence the growth of the nucleic acid isolation and purification market. A detailed analysis of key industry players has been conducted to provide insights into their business overview, product portfolio, key strategies such as product launches, collaborations, partnerships, expansions, agreements, and recent developments associated with the nucleic acid isolation and purification market. Competitive analysis of top players and upcoming startups in the nucleic acid isolation and purification market ecosystem is also covered in this report. Key Benefits of Buying the Report The report will help market leaders and new entrants by providing the closest approximations of revenue for the overall nucleic acid isolation and purification market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain insights to better position their business and develop suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide information on the key market drivers, restraints, opportunities, and challenges. The report provides insights into the following points: Analysis of key drivers (routine PCR/qPCR and NGS testing scaling across care and research, expanding public health genomic surveillance in more countries), restraints (high cost and time required for high-volume testing), opportunities (automation impacting throughput, traceability, and staffing resilience, premium NAIP products for cfDNA, oncology, and low-input workflows), and challenges (variability due to PCR inhibitors and matrix effects) influencing the growth of the market. • Product Development/Innovation: Detailed insights on newly launched products of the nucleic acid isolation and purification market • Market Development: Comprehensive information about lucrative markets - the report analyzes the market across varied regions. • Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the nucleic acid isolation and purification market • Competitive Assessment: Thermo Fisher Scientific Inc. (US), Merck KGaA (Germany), QIAGEN (Germany), F. Hoffmann-La Roche Ltd. (Switzerland), Promega Corporation (US), Agilent Technologies, Inc. (US), Danaher(US), Bio-Rad Laboratories, Inc. (US), Illumina, Inc. (US), Takara Bio Inc. (Japan), New England Biolabs (US), Abcam Plc (UK), KILPEST India Limited (India), Apical Scientific Sdn. Bhd. (Malaysia), Endress+Hauser Group Services AG (Switzerland), GENAXXON bioscience GmbH (Germany), and LGC Biosearch Technologies (US), among others
目錄 Table of Contents
1 INTRODUCTION 45 1.1 STUDY OBJECTIVES 45 1.2 MARKET DEFINITION 45 1.3 STUDY SCOPE 46 1.3.1 MARKET SEGMENTATION & REGIONAL SCOPE 46 1.4 INCLUSIONS & EXCLUSIONS 47 1.4.1 YEARS CONSIDERED 48 1.4.2 CURRENCY CONSIDERED 48 1.5 STAKEHOLDERS 49 1.6 SUMMARY OF CHANGES 49 2 EXECUTIVE SUMMARY 51 2.1 MARKET HIGHLIGHTS & KEY INSIGHTS 51 2.2 KEY MARKET PARTICIPANTS: MAPPING OF STRATEGIC DEVELOPMENTS 53 2.3 DISRUPTIVE TRENDS IN NUCLEIC ACID ISOLATION AND PURIFICATION MARKET 54 2.4 HIGH-GROWTH SEGMENTS 55 2.5 REGIONAL SNAPSHOT: MARKET SIZE, GROWTH RATE, AND FORECAST 56 3 PREMIUM INSIGHTS 58 3.1 NUCLEIC ACID ISOLATION AND PURIFICATION MARKET OVERVIEW 58 3.2 NORTH AMERICA: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET, BY PRODUCT 59 3.3 NUCLEIC ACID ISOLATION AND PURIFICATION MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 60 3.4 NUCLEIC ACID ISOLATION AND PURIFICATION MARKET SHARE, BY END USER, 2026 VS 2031 (%) 61 4 MARKET OVERVIEW 62 4.1 INTRODUCTION 62 4.2 MARKET DYNAMICS 62 4.2.1 DRIVERS 64 4.2.1.1 Rising adoption of automated nucleic acid extraction systems 64 4.2.1.2 Increasing need for high-purity and inhibitor-free nucleic acid recovery 64 4.2.1.3 Broadening use of magnetic bead-based purification chemistries 65 4.2.1.4 Growth in complex and difficult sample-type processing 65 4.2.2 RESTRAINTS 65 4.2.2.1 Price pressure and partial commoditization of routine extraction kits 65 4.2.2.2 Continued use of manual and low-cost in-house methods in small & mid-sized labs 66 4.2.2.3 Workflow substitution in selected use cases 66 4.2.3 OPPORTUNITIES 66 4.2.3.1 Premium extraction solutions for low-input and cell-free nucleic acids 66 4.2.3.2 Expansion of automated benchtop and mid-throughput extraction platforms 67 4.2.3.3 Workflow integration with quantitation, tracking, and digital reporting 67 4.2.3.4 Application-specific extraction workflows in biopharma and CGT 67 4.2.4 CHALLENGES 68 4.2.4.1 Pre-analytical variability that affects extraction output 68 4.2.4.2 Removal of inhibitors and contaminants from difficult matrices 68 4.2.4.3 Standardization and validation for regulated or sensitive workflows 68 4.3 UNMET NEEDS & WHITE SPACES 69 4.4 INTERCONNECTED MARKETS & CROSS-SECTOR OPPORTUNITIES 70 4.5 STRATEGIC MOVES BY TIER-1/2/3 PLAYERS 72 5 INDUSTRY TRENDS 73 5.1 PORTER’S FIVE FORCES ANALYSIS 73 5.1.1 THREAT OF NEW ENTRANTS 74 5.1.2 THREAT OF SUBSTITUTES 74 5.1.3 BARGAINING POWER OF BUYERS 74 5.1.4 BARGAINING POWER OF SUPPLIERS 74 5.1.5 INTENSITY OF COMPETITIVE RIVALRY 74 5.2 MACROECONOMIC OUTLOOK 75 5.2.1 INTRODUCTION 75 5.2.2 GDP TRENDS & FORECAST 75 5.2.3 TRENDS IN GLOBAL NUCLEIC ACID ISOLATION AND PURIFICATION MARKET 75 5.2.4 TRENDS IN HEALTHCARE EXPENDITURE 77 5.3 VALUE CHAIN ANALYSIS 78 5.4 SUPPLY CHAIN ANALYSIS 81 5.5 ECOSYSTEM ANALYSIS 82 5.5.1 EMERGING BUSINESS MODELS & ECOSYSTEM SHIFTS 83 5.6 PRICING ANALYSIS 85 5.6.1 INDICATIVE SELLING PRICE OF KEY PLAYERS, BY PRODUCT, 2025 85 5.6.2 INDICATIVE SELLING PRICE OF NAIP PRODUCTS, BY REGION, 2025 86 5.7 KEY CONFERENCES & EVENTS 87 5.8 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 88 5.9 INVESTMENT/FUNDING ACTIVITY 89 5.10 CASE STUDY ANALYSIS 90 5.11 IMPACT OF 2025 US TARIFFS ON NUCLEIC ACID ISOLATION AND PURIFICATION MARKET 92 5.11.1 INTRODUCTION 92 5.11.2 KEY TARIFF RATES 92 5.11.3 PRICE IMPACT ANALYSIS 93 5.11.4 IMPACT ON COUNTRY/REGION 94 5.11.4.1 US 94 5.11.4.2 Europe 94 5.11.4.3 Asia Pacific 94 5.11.5 IMPACT ON END-USE INDUSTRIES 95 5.11.5.1 Hospitals & diagnostic centers 95 5.11.5.2 Academic & government research institutes 95 5.11.5.3 Pharmaceutical & biotechnology companies 96 5.11.5.4 Contract research organizations (CROs) 96 5.11.5.5 Other end users 96 6 TECHNOLOGICAL ADVANCEMENTS, AI-DRIVEN IMPACT, PATENTS, INNOVATIONS, AND FUTURE APPLICATIONS 98 6.1 TECHNOLOGY ANALYSIS 98 6.1.1 KEY TECHNOLOGIES 98 6.1.1.1 Silica membrane/spin column purification 98 6.1.1.2 Magnetic bead-based purification 98 6.1.1.3 Reagent-based extraction/organic extraction 98 6.1.2 COMPLEMENTARY TECHNOLOGIES 99 6.1.2.1 Sample lysis & homogenization technologies 99 6.1.2.2 Centrifugation & vacuum manifold systems 99 6.1.3 ADJACENT TECHNOLOGIES 99 6.1.3.1 PCR & qPCR technologies 99 6.2 TECHNOLOGY/PRODUCT ROADMAP 99 6.3 PATENT ANALYSIS 102 6.3.1 TOP APPLICANTS/OWNERS (COMPANIES) FOR NUCLEIC ACID ISOLATION AND PURIFICATION PRODUCT/TECHNOLOGY PATENTS, 2015–2025 102 6.4 FUTURE APPLICATIONS 104 6.5 IMPACT OF AI/GEN AI ON NUCLEIC ACID ISOLATION AND PURIFICATION MARKET 104 6.5.1 TOP USE CASES & MARKET POTENTIAL 105 6.5.2 CASE STUDIES OF AI IMPLEMENTATION IN NUCLEIC ACID ISOLATION AND PURIFICATION MARKET 106 6.5.3 INTERCONNECTED ADJACENT ECOSYSTEMS & IMPACT ON MARKET PLAYERS 107 6.5.4 CLIENTS’ READINESS TO ADOPT GENERATIVE AI IN NUCLEIC ACID ISOLATION AND PURIFICATION MARKET 107 6.6 SUCCESS STORIES & REAL-WORLD APPLICATIONS 108 7 SUSTAINABILITY & REGULATORY LANDSCAPE 110 7.1 REGULATORY LANDSCAPE 110 7.1.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 110 7.1.2 REGULATORY FRAMEWORK/KEY REGULATIONS 112 7.1.2.1 North America 112 7.1.2.1.1 US 112 7.1.2.1.2 Canada 114 7.1.2.2 Europe 115 7.1.2.2.1 Germany 115 7.1.2.2.2 France 116 7.1.2.2.3 UK 116 7.1.2.3 Asia Pacific 116 7.1.2.3.1 Japan 116 7.1.2.3.2 China 117 7.1.2.3.3 India 118 7.1.2.3.4 South Korea 118 7.1.2.4 Latin America 119 7.1.2.4.1 Brazil 119 7.1.2.5 Middle East 120 7.1.2.5.1 Saudi Arabia 120 7.1.3 INDUSTRY STANDARDS 120 7.2 SUSTAINABILITY IMPACT & REGULATORY POLICY INITIATIVES 121 7.3 CERTIFICATIONS, LABELING, AND ECO-STANDARDS 122 8 CUSTOMER LANDSCAPE & BUYER BEHAVIOR 123 8.1 DECISION-MAKING PROCESS 123 8.2 BUYER STAKEHOLDERS & BUYING EVALUATION CRITERIA 123 8.2.1 KEY STAKEHOLDERS IN BUYING PROCESS 123 8.2.2 KEY BUYING CRITERIA, BY END USER 124 8.3 ADOPTION BARRIERS & INTERNAL CHALLENGES 125 8.4 UNMET NEEDS FROM VARIOUS END-USE INDUSTRIES 126 8.5 MARKET PROFITABILITY 127 9 NUCLEIC ACID ISOLATION AND PURIFICATION MARKET, BY PRODUCT 128 9.1 INTRODUCTION 129 9.2 KITS 130 9.2.1 KITS TO ACCOUNT FOR LARGEST SHARE OF MARKET DURING FORECAST PERIOD 130 9.3 REAGENTS 134 9.3.1 AVAILABILITY OF READY-TO-USE REAGENTS TO DRIVE GROWTH 134 9.4 INSTRUMENTS 138 9.4.1 AUTOMATIC INSTRUMENTS 142 9.4.1.1 Benefits of automatic instruments to drive growth 142 9.4.2 MANUAL INSTRUMENTS 146 9.4.2.1 Growing demand for nucleic acid isolation and purification in research and clinical applications to drive growth 146   10 NUCLEIC ACID ISOLATION AND PURIFICATION MARKET, BY METHOD 150 10.1 INTRODUCTION 151 10.2 MAGNETIC BEAD-BASED ISOLATION AND PURIFICATION 151 10.2.1 MAGNETIC BEAD-BASED ISOLATION AND PURIFICATION SEGMENT TO REGISTER HIGHEST CAGR DURING FORECAST PERIOD 151 10.3 REAGENT-BASED ISOLATION AND PURIFICATION 155 10.3.1 REAGENT-BASED ISOLATION AND PURIFICATION SEGMENT TO REGISTER STEADY GROWTH DURING FORECAST PERIOD 155 10.4 COLUMN-BASED ISOLATION AND PURIFICATION 159 10.4.1 GROWING POPULARITY OF COLUMN-BASED ISOLATION AND PURIFICATION IN CURRENT KITS TO BOOST MARKET 159 10.5 OTHER ISOLATION AND PURIFICATION METHODS 163 11 NUCLEIC ACID ISOLATION AND PURIFICATION MARKET, BY TYPE 167 11.1 INTRODUCTION 168 11.2 PLASMID DNA ISOLATION AND PURIFICATION 169 11.2.1 PLASMID DNA ISOLATION AND PURIFICATION TO ACCOUNT FOR LARGEST SHARE OF MARKET 169 11.3 TOTAL RNA ISOLATION AND PURIFICATION 173 11.3.1 WIDE USE OF TOTAL RNA ISOLATION AND PURIFICATION FOR RESEARCH AND DIAGNOSTIC APPLICATIONS TO BOOST MARKET 173 11.4 GENOMIC DNA ISOLATION AND PURIFICATION 176 11.4.1 IMPORTANCE OF GENOMIC DNA ISOLATION IN GENETIC-BASED TESTS TO SUPPORT GROWTH 176 11.5 MESSENGER RNA ISOLATION AND PURIFICATION 180 11.5.1 ROLE PLAYED BY MESSENGER RNA ISOLATION AND PURIFICATION IN GENE EXPRESSION AND TRANSCRIPTOMICS TO DRIVE GROWTH 180 11.6 CIRCULATING NUCLEIC ACID ISOLATION AND PURIFICATION 184 11.6.1 ABILITY OF CIRCULATING NAIP TO ENABLE COLLECTION OF GENETIC INFORMATION FROM BODY FLUIDS TO BOOST ADOPTION 184 11.7 MICRORNA ISOLATION AND PURIFICATION 187 11.7.1 GROWING APPLICATIONS OF MICRORNA ISOLATION AND PURIFICATION IN DRUG DEVELOPMENT RESEARCH TO FUEL GROWTH 187 11.8 OTHER NUCLEIC ACID ISOLATION AND PURIFICATION TYPES 191 12 NUCLEIC ACID ISOLATION AND PURIFICATION MARKET, BY SAMPLE TYPE 195 12.1 INTRODUCTION 196 12.2 CELLULAR SAMPLES 196 12.2.1 WBCS 201 12.2.1.1 Strong demand from routine blood-based genomics and diagnostic testing workflows to boost market 201 12.2.2 CULTURED CELLS 204 12.2.2.1 Core segment supporting drug discovery, cell biology, and biopharma R&D applications 204   12.2.3 BACTERIAL 208 12.2.3.1 Rising adoption in infectious disease, microbiome, and environmental testing workflows to fuel market growth 208 12.2.4 OTHER CELLULAR SAMPLES 211 12.3 PRESERVED TISSUE SAMPLES 215 12.3.1 FRESH/FROZEN TISSUES 219 12.3.1.1 Preferred for high-quality nucleic acid recovery in research and translational studies 219 12.3.2 FFPE (FORMALIN-FIXED PARAFFIN-EMBEDDED) 222 12.3.2.1 Fastest-growing segment fueled by increasing use of archived clinical samples in oncology 222 12.3.3 OTHER PRESERVED TISSUE SAMPLES 226 12.4 CELL-FREE SAMPLES 229 12.4.1 CFDNA/CTDNA 233 12.4.1.1 Key growth driver enabling liquid biopsy and real-time disease monitoring 233 12.4.2 OTHER CELL-FREE SAMPLES 237 12.5 OTHER SAMPLES 240 13 NUCLEIC ACID ISOLATION AND PURIFICATION MARKET, BY APPLICATION 244 13.1 INTRODUCTION 245 13.2 DIAGNOSTICS 245 13.2.1 DIAGNOSTIC APPLICATIONS TO DOMINATE MARKET DURING FORECAST PERIOD 245 13.3 DRUG DISCOVERY & DEVELOPMENT 249 13.3.1 POTENTIAL OF NAIP TO HELP IN DEVELOPMENT OF DRUGS FOR RARE DISEASES TO BOOST MARKET 249 13.4 PERSONALIZED MEDICINE 253 13.4.1 RISING INCIDENCE OF CANCER AND INCREASING RESEARCH AND FUNDING TO DRIVE GROWTH 253 13.5 AGRICULTURE & ANIMAL RESEARCH 257 13.5.1 FAVORABLE FUNDING SCENARIO TO SUPPORT MARKET GROWTH 257 13.6 OTHER APPLICATIONS 261 14 NUCLEIC ACID ISOLATION AND PURIFICATION MARKET, BY END USER 265 14.1 INTRODUCTION 266 14.2 HOSPITALS & DIAGNOSTIC CENTERS 267 14.2.1 RISING FOCUS ON PERSONALIZED MEDICINE IN HOSPITALS TO DRIVE MARKET GROWTH 267 14.3 ACADEMIC & GOVERNMENT RESEARCH INSTITUTES 271 14.3.1 INCREASE IN RESEARCH INTENSITY TO DRIVE USAGE OF NUCLEIC ACID ISOLATION AND PURIFICATION SYSTEMS 271 14.4 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES 275 14.4.1 INCREASING NUMBER OF RESEARCH PROJECTS IN GENOMICS AND RELATED AREAS TO DRIVE SEGMENT GROWTH 275 14.5 CONTRACT RESEARCH ORGANIZATIONS 279 14.5.1 CONTRACT RESEARCH ORGANIZATIONS TO REGISTER STEADY GROWTH DURING FORECAST PERIOD 279 14.6 OTHER END USERS 283 15 NUCLEIC ACID ISOLATION AND PURIFICATION MARKET, BY REGION 287 15.1 INTRODUCTION 288 15.2 NORTH AMERICA 288 15.2.1 US 295 15.2.1.1 Government and private funding to support market growth 295 15.2.2 CANADA 301 15.2.2.1 Growing investments in genomics to boost market demand 301 15.3 EUROPE 306 15.3.1 GERMANY 313 15.3.1.1 Germany to dominate market in Europe 313 15.3.2 UK 318 15.3.2.1 Government support for research through investments, funds, and grants to support market growth 318 15.3.3 FRANCE 322 15.3.3.1 Increasing number of established biotech facilities to drive market growth 322 15.3.4 ITALY 326 15.3.4.1 Government support to drive market growth in Italy 326 15.3.5 SPAIN 331 15.3.5.1 High adoption of advanced diagnostic technologies to drive market growth in Spain 331 15.3.6 REST OF EUROPE 336 15.4 ASIA PACIFIC 340 15.4.1 CHINA 348 15.4.1.1 Strong domestic genomics scale and tightening IVD framework to drive NAIP adoption 348 15.4.2 JAPAN 353 15.4.2.1 Whole-genome medicine and structured clinical implementation to support premium NAIP demand 353 15.4.3 INDIA 357 15.4.3.1 National genomics initiatives and rising domestic manufacturing to expand NAIP opportunities 357 15.4.4 AUSTRALIA 362 15.4.4.1 Precision health funding and rare-disease genomics to support advanced NAIP workflows 362 15.4.5 SOUTH KOREA 366 15.4.5.1 Support from governments to drive market in region 366 15.4.6 REST OF ASIA PACIFIC (ROAPAC) 371   15.5 LATIN AMERICA 375 15.5.1 BRAZIL 380 15.5.1.1 Brazil to dominate LATAM market 380 15.5.2 MEXICO 384 15.5.2.1 Favorable trade agreements to support imports and improve access to NAIP instruments in Mexico 384 15.5.3 REST OF LATIN AMERICA 389 15.6 MIDDLE EAST 393 15.6.1 GCC COUNTRIES 398 15.6.1.1 Saudi Arabia 403 15.6.1.1.1 National genomics strategy and precision medicine expansion to accelerate NAIP demand 403 15.6.1.2 UAE 407 15.6.1.2.1 Molecular lab standardization and genomics-led healthcare investment to strengthen NAIP adoption 407 15.6.1.3 Rest of GCC Countries 411 15.6.2 REST OF MIDDLE EAST 416 15.7 AFRICA 421 15.7.1 GOVERNMENT SUPPORT FOR RESEARCH STUDIES TO FUEL GROWTH 421 16 COMPETITIVE LANDSCAPE 426 16.1 INTRODUCTION 426 16.2 STRATEGIES ADOPTED BY KEY PLAYERS/RIGHT TO WIN 426 16.3 REVENUE ANALYSIS, 2021–2025 428 16.4 MARKET SHARE ANALYSIS, 2025 429 16.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2025 431 16.5.1 STARS 431 16.5.2 EMERGING LEADERS 431 16.5.3 PERVASIVE PLAYERS 432 16.5.4 PARTICIPANTS 432 16.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2025 433 16.5.5.1 Company footprint 433 16.5.5.2 Region footprint 434 16.5.5.3 Product footprint 435 16.5.5.4 Method footprint 436 16.5.5.5 Application footprint 437 16.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2025 438 16.6.1 PROGRESSIVE COMPANIES 438 16.6.2 RESPONSIVE COMPANIES 438 16.6.3 DYNAMIC COMPANIES 438 16.6.4 STARTING BLOCKS 438   16.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2025 440 16.6.5.1 List of key startups/SMEs 440 16.6.5.2 Competitive benchmarking of key startups/SMEs 441 16.7 COMPANY VALUATION & FINANCIAL METRICS 442 16.7.1 FINANCIAL METRICS 442 16.7.2 COMPANY VALUATION 442 16.8 BRAND/PRODUCT COMPARISON 443 16.8.1 BRAND/PRODUCT COMPARATIVE ANALYSIS, BY PRODUCT 443 16.9 COMPETITIVE SCENARIO 444 16.9.1 PRODUCT LAUNCHES 444 16.9.2 DEALS 445 17 COMPANY PROFILES 447 17.1 KEY PLAYERS 447 17.1.1 THERMO FISHER SCIENTIFIC INC. 447 17.1.1.1 Business overview 447 17.1.1.2 Products offered 448 17.1.1.3 Recent developments 450 17.1.1.3.1 Product launches 450 17.1.1.3.2 Expansions 450 17.1.1.3.3 Other developments 451 17.1.1.4 MnM view 451 17.1.1.4.1 Key strengths 451 17.1.1.4.2 Strategic choices 451 17.1.1.4.3 Weaknesses & competitive threats 451 17.1.2 QIAGEN N.V. 452 17.1.2.1 Business overview 452 17.1.2.2 Products offered 453 17.1.2.3 Recent developments 454 17.1.2.3.1 Product launches 454 17.1.2.3.2 Deals 455 17.1.2.4 MnM view 455 17.1.2.4.1 Key strengths 455 17.1.2.4.2 Strategic choices 455 17.1.2.4.3 Weaknesses & competitive threats 455 17.1.3 MERCK KGAA 456 17.1.3.1 Business overview 456 17.1.3.2 Products offered 457 17.1.3.3 Recent developments 461 17.1.3.3.1 Product launches 461 17.1.3.4 MnM view 462 17.1.3.4.1 Key strengths 462 17.1.3.4.2 Strategic choices 462 17.1.3.4.3 Weaknesses & competitive threats 462 17.1.4 F. HOFFMANN-LA ROCHE LTD. 463 17.1.4.1 Business overview 463 17.1.4.2 Products offered 464 17.1.4.3 Recent developments 467 17.1.4.3.1 Other developments 467 17.1.4.4 MnM view 467 17.1.4.4.1 Key strengths 467 17.1.4.4.2 Strategic choices 467 17.1.4.4.3 Weaknesses & competitive threats 467 17.1.5 DANAHER CORPORATION 468 17.1.5.1 Business overview 468 17.1.5.2 Products offered 469 17.1.5.3 Recent developments 472 17.1.5.3.1 Deals 472 17.1.5.4 MnM view 472 17.1.5.4.1 Key strengths 472 17.1.5.4.2 Strategic choices 473 17.1.5.4.3 Weaknesses & competitive threats 473 17.1.6 PROMEGA CORPORATION 474 17.1.6.1 Business overview 474 17.1.6.2 Products offered 474 17.1.6.3 Recent developments 477 17.1.6.3.1 Deals 477 17.1.7 AGILENT TECHNOLOGIES, INC. 478 17.1.7.1 Business overview 478 17.1.7.2 Products offered 479 17.1.7.3 Recent developments 480 17.1.7.3.1 Other Developments 480 17.1.8 BIO-RAD LABORATORIES, INC. 481 17.1.8.1 Business overview 481 17.1.8.2 Products offered 483 17.1.9 ILLUMINA, INC. 484 17.1.9.1 Business overview 484 17.1.9.2 Products offered 485 17.1.9.3 Recent developments 486 17.1.9.3.1 Product launches 486 17.1.10 TAKARA BIO INC. 487 17.1.10.1 Business overview 487 17.1.10.2 Products offered 488   17.1.11 NEW ENGLAND BIOLABS 492 17.1.11.1 Business overview 492 17.1.11.2 Products offered 492 17.1.11.3 Recent developments 495 17.1.11.3.1 Product launches 495 17.1.12 A&A BIOTECHNOLOGY 496 17.1.12.1 Business overview 496 17.1.12.2 Products offered 497 17.1.13 REVVITY INC. 498 17.1.13.1 Business overview 498 17.1.13.2 Products offered 500 17.1.14 BIONEER CORPORATION 501 17.1.14.1 Business overview 501 17.1.14.2 Products offered 502 17.1.15 HIMEDIA LABORATORIES PRIVATE LIMITED 503 17.1.15.1 Business overview 503 17.1.15.2 Products offered 503 17.2 OTHER PLAYERS 504 17.2.1 KILPEST INDIA LIMITED 504 17.2.2 APICAL SCIENTIFIC SDN. BHD. 505 17.2.3 ENDRESS+HAUSER GROUP SERVICES AG 506 17.2.4 GENAXXON BIOSCIENCE GMBH 507 17.2.5 LGC BIOSEARCH TECHNOLOGIES 508 17.2.6 ZYMO RESEARCH CORPORATION 509 17.2.7 NORGEN BIOTEK CORP. 512 17.2.8 OMEGA BIO-TEK, INC. 513 17.2.9 FAVORGEN BIOTECH CORPORATION 515 17.2.10 TIANGEN BIOTECH(BEIJING)CO., LTD. 516 17.2.11 AUTOGEN INC. 517 17.2.12 PCR BIOSYSTEMS 518 17.2.13 BIOGENUIX 519 17.2.14 MP BIOMEDICALS 520 17.2.15 NANJING VAZYME BIOTECH CO., LTD. 521 18 RESEARCH METHODOLOGY 522 18.1 RESEARCH DATA 522 18.1.1 SECONDARY DATA 523 18.1.1.1 Key data from secondary sources 523 18.1.2 PRIMARY DATA 524 18.1.2.1 Key data from primary sources 524 18.1.2.2 Key primary participants 524 18.1.2.3 Breakdown of primary interviews 525 18.1.2.4 Key industry insights 526 18.2 MARKET SIZE ESTIMATION 526 18.2.1 SEGMENTAL MARKET SIZE ESTIMATION 529 18.3 MARKET GROWTH RATE PROJECTIONS 531 18.4 FACTOR ANALYSIS 532 18.5 DATA TRIANGULATION 533 18.6 RESEARCH ASSUMPTIONS 534 18.7 RESEARCH LIMITATIONS & RISK ASSESSMENT 535 18.8 SRISK ASSESSMENT 535 19 APPENDIX 536 19.1 DISCUSSION GUIDE 536 19.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 540 19.3 CUSTOMIZATION OPTIONS 542 19.4 RELATED REPORTS 543 19.5 AUTHOR DETAILS 544
圖表清單 List of Tables & Figures
TABLE 1 NUCLEIC ACID ISOLATION AND PURIFICATION MARKET: IMPACT ANALYSIS 63 TABLE 2 NEXT-GENERATION SEQUENCING MARKET, BY REGION, 2024–2031 (USD MILLION) 70 TABLE 3 NUCLEIC ACID ISOLATION AND PURIFICATION MARKET: PORTER’S FIVE FORCES ANALYSIS 74 TABLE 4 HEALTH EXPENDITURE AND FINANCING, 2015–2024 (IN PERCENTAGE OF GDP) 77 TABLE 5 NUCLEIC ACID ISOLATION AND PURIFICATION MARKET: ROLE IN ECOSYSTEM 82 TABLE 6 INDICATIVE SELLING PRICE OF KEY PLAYERS, BY PRODUCT, 2025 85 TABLE 7 INDICATIVE SELLING PRICE OF NAIP PRODUCTS, BY REGION, 2025 86 TABLE 8 NUCLEIC ACID ISOLATION AND PURIFICATION MARKET: KEY CONFERENCES & EVENTS, 2026–2027 87 TABLE 9 CASE STUDY 1: DNA EXTRACTION FROM ARCHEOLOGICAL AND RECENT SKELETAL REMAINS 90 TABLE 10 CASE STUDY 2: CLINICAL LAB AUTOMATION FOR ROUTINE MOLECULAR SAMPLE PREPARATION 91 TABLE 11 CASE STUDY 3: AUTOMATED EXTRACTION OF FFPE SAMPLES FOR ONCOLOGY/NGS WORKFLOWS 91 TABLE 12 US-ADJUSTED RECIPROCAL TARIFF RATES 92 TABLE 13 NUCLEIC ACID ISOLATION AND PURIFICATION MARKET: KEY COMPANIES’ TECHNOLOGY/PRODUCT ROADMAP 100 TABLE 14 DETAILED ANALYSIS OF KEY PATENTS IN NUCLEIC ACID ISOLATION AND PURIFICATION MARKET 103 TABLE 15 CASE STUDIES OF AI IMPLEMENTATION IN NUCLEIC ACID ISOLATION AND PURIFICATION 106 TABLE 16 CLIENTS’ READINESS TO ADOPT GENERATIVE AI IN NUCLEIC ACID ISOLATION AND PURIFICATION MARKET 108 TABLE 17 KEY SUCCESS STORIES WITH RESPECT TO REAL-WORLD APPLICATION IN NUCLEIC ACID ISOLATION AND PURIFICATION MARKET 109 TABLE 18 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 110 TABLE 19 US FDA: MEDICAL DEVICE CLASSIFICATION 112 TABLE 20 US: MEDICAL DEVICE REGULATORY APPROVAL PROCESS 113 TABLE 21 EUROPE: CLASSIFICATION OF DEVICES 115 TABLE 22 JAPAN: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS 117 TABLE 23 CHINA: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS 117 TABLE 24 SOUTH KOREA: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS 119 TABLE 25 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY PRODUCT (%) 124 TABLE 26 KEY BUYING CRITERIA, BY END USER 124 TABLE 27 UNMET NEED ACROSS DIFFERENT END USERS IN NUCLEIC ACID ISOLATION AND PURIFICATION MARKET 126 TABLE 28 NUCLEIC ACID ISOLATION AND PURIFICATION MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 129 TABLE 29 NUCLEIC ACID ISOLATION AND PURIFICATION KITS MARKET, BY REGION, 2024–2031 (USD MILLION) 131 TABLE 30 NORTH AMERICA: NUCLEIC ACID ISOLATION AND PURIFICATION KITS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 131 TABLE 31 EUROPE: NUCLEIC ACID ISOLATION AND PURIFICATION KITS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 132 TABLE 32 ASIA PACIFIC: NUCLEIC ACID ISOLATION AND PURIFICATION KITS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 132 TABLE 33 LATIN AMERICA: NUCLEIC ACID ISOLATION AND PURIFICATION KITS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 133 TABLE 34 MIDDLE EAST: NUCLEIC ACID ISOLATION AND PURIFICATION KITS MARKET, BY REGION, 2024–2031 (USD MILLION) 133 TABLE 35 GCC COUNTRIES: NUCLEIC ACID ISOLATION AND PURIFICATION KITS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 133 TABLE 36 NUCLEIC ACID ISOLATION AND PURIFICATION REAGENTS MARKET, BY REGION, 2024–2031 (USD MILLION) 135 TABLE 37 NORTH AMERICA: NUCLEIC ACID ISOLATION AND PURIFICATION REAGENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 135 TABLE 38 EUROPE: NUCLEIC ACID ISOLATION AND PURIFICATION REAGENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 136 TABLE 39 ASIA PACIFIC: NUCLEIC ACID ISOLATION AND PURIFICATION REAGENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 136 TABLE 40 LATIN AMERICA: NUCLEIC ACID ISOLATION AND PURIFICATION REAGENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 137 TABLE 41 MIDDLE EAST: NUCLEIC ACID ISOLATION AND PURIFICATION REAGENTS MARKET, BY REGION, 2024–2031 (USD MILLION) 137 TABLE 42 GCC COUNTRIES: NUCLEIC ACID ISOLATION AND PURIFICATION REAGENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 137 TABLE 43 NUCLEIC ACID ISOLATION AND PURIFICATION INSTRUMENTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 139 TABLE 44 NUCLEIC ACID ISOLATION AND PURIFICATION INSTRUMENTS MARKET, BY REGION, 2024–2031 (USD MILLION) 139 TABLE 45 NORTH AMERICA: NUCLEIC ACID ISOLATION AND PURIFICATION INSTRUMENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 140 TABLE 46 EUROPE: NUCLEIC ACID ISOLATION AND PURIFICATION INSTRUMENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 140 TABLE 47 ASIA PACIFIC: NUCLEIC ACID ISOLATION AND PURIFICATION INSTRUMENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 141 TABLE 48 LATIN AMERICA: NUCLEIC ACID ISOLATION AND PURIFICATION INSTRUMENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 141 TABLE 49 MIDDLE EAST: NUCLEIC ACID ISOLATION AND PURIFICATION INSTRUMENTS MARKET, BY REGION, 2024–2031 (USD MILLION) 142 TABLE 50 GCC COUNTRIES: NUCLEIC ACID ISOLATION AND PURIFICATION INSTRUMENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 142 TABLE 51 NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR AUTOMATIC INSTRUMENTS, BY REGION, 2024–2031 (USD MILLION) 143 TABLE 52 NORTH AMERICA: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR AUTOMATIC INSTRUMENTS, BY COUNTRY, 2024–2031 (USD MILLION) 143 TABLE 53 EUROPE: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR AUTOMATIC INSTRUMENTS, BY COUNTRY, 2024–2031 (USD MILLION) 144 TABLE 54 ASIA PACIFIC: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR AUTOMATIC INSTRUMENTS, BY COUNTRY, 2024–2031 (USD MILLION) 144 TABLE 55 LATIN AMERICA: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR AUTOMATIC INSTRUMENTS, BY COUNTRY, 2024–2031 (USD MILLION) 145 TABLE 56 MIDDLE EAST: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR AUTOMATIC INSTRUMENTS, BY REGION, 2024–2031 (USD MILLION) 145 TABLE 57 GCC COUNTRIES: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR AUTOMATIC INSTRUMENTS, BY COUNTRY, 2024–2031 (USD MILLION) 145 TABLE 58 NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR MANUAL INSTRUMENTS, BY REGION, 2024–2031 (USD MILLION) 146 TABLE 59 NORTH AMERICA: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR MANUAL INSTRUMENTS, BY COUNTRY, 2024–2031 (USD MILLION) 147 TABLE 60 EUROPE: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR MANUAL INSTRUMENTS, BY COUNTRY, 2024–2031 (USD MILLION) 147 TABLE 61 ASIA PACIFIC: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR MANUAL INSTRUMENTS, BY COUNTRY, 2024–2031 (USD MILLION) 148 TABLE 62 LATIN AMERICA: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR MANUAL INSTRUMENTS, BY COUNTRY, 2024–2031 (USD MILLION) 148 TABLE 63 MIDDLE EAST: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR MANUAL INSTRUMENTS, BY REGION, 2024–2031 (USD MILLION) 149 TABLE 64 GCC COUNTRIES: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR MANUAL INSTRUMENTS, BY COUNTRY, 2024–2031 (USD MILLION) 149 TABLE 65 NUCLEIC ACID ISOLATION AND PURIFICATION MARKET, BY METHOD, 2024–2031 (USD MILLION) 151 TABLE 66 MAGNETIC BEAD-BASED ISOLATION AND PURIFICATION MARKET, BY REGION, 2024–2031 (USD MILLION) 152 TABLE 67 NORTH AMERICA: MAGNETIC BEAD-BASED ISOLATION AND PURIFICATION MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 153 TABLE 68 EUROPE: MAGNETIC BEAD-BASED ISOLATION AND PURIFICATION MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 153 TABLE 69 ASIA PACIFIC: MAGNETIC BEAD-BASED ISOLATION AND PURIFICATION MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 154 TABLE 70 LATIN AMERICA: MAGNETIC BEAD-BASED ISOLATION AND PURIFICATION MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 154 TABLE 71 MIDDLE EAST: MAGNETIC BEAD-BASED ISOLATION AND PURIFICATION MARKET, BY REGION, 2024–2031 (USD MILLION) 155 TABLE 72 GCC COUNTRIES: MAGNETIC BEAD-BASED ISOLATION AND PURIFICATION MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 155 TABLE 73 REAGENT-BASED ISOLATION AND PURIFICATION MARKET, BY REGION, 2024–2031 (USD MILLION) 156 TABLE 74 NORTH AMERICA: REAGENT-BASED ISOLATION AND PURIFICATION MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 157 TABLE 75 EUROPE: REAGENT-BASED ISOLATION AND PURIFICATION MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 157 TABLE 76 ASIA PACIFIC: REAGENT-BASED ISOLATION AND PURIFICATION MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 158 TABLE 77 LATIN AMERICA: REAGENT-BASED ISOLATION AND PURIFICATION MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 158 TABLE 78 MIDDLE EAST: REAGENT-BASED ISOLATION AND PURIFICATION MARKET, BY REGION, 2024–2031 (USD MILLION) 159 TABLE 79 GCC COUNTRIES: REAGENT-BASED ISOLATION AND PURIFICATION MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 159 TABLE 80 COLUMN-BASED ISOLATION AND PURIFICATION MARKET, BY REGION, 2024–2031 (USD MILLION) 160 TABLE 81 NORTH AMERICA: COLUMN-BASED ISOLATION AND PURIFICATION MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 160 TABLE 82 EUROPE: COLUMN-BASED ISOLATION AND PURIFICATION MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 161 TABLE 83 ASIA PACIFIC: COLUMN-BASED ISOLATION AND PURIFICATION MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 161 TABLE 84 LATIN AMERICA: COLUMN-BASED ISOLATION AND PURIFICATION MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 162 TABLE 85 MIDDLE EAST: COLUMN-BASED ISOLATION AND PURIFICATION MARKET, BY REGION, 2024–2031 (USD MILLION) 162 TABLE 86 GCC COUNTRIES: COLUMN-BASED ISOLATION AND PURIFICATION MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 162 TABLE 87 OTHER ISOLATION AND PURIFICATION METHODS MARKET, BY REGION, 2024–2031 (USD MILLION) 163 TABLE 88 NORTH AMERICA: OTHER ISOLATION AND PURIFICATION METHODS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 164 TABLE 89 EUROPE: OTHER ISOLATION AND PURIFICATION METHODS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 164 TABLE 90 ASIA PACIFIC: OTHER ISOLATION AND PURIFICATION METHODS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 165 TABLE 91 LATIN AMERICA: OTHER ISOLATION AND PURIFICATION METHODS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 165 TABLE 92 MIDDLE EAST: OTHER ISOLATION AND PURIFICATION METHODS MARKET, BY REGION, 2024–2031 (USD MILLION) 166 TABLE 93 GCC COUNTRIES: OTHER ISOLATION AND PURIFICATION METHODS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 166 TABLE 94 NUCLEIC ACID ISOLATION AND PURIFICATION MARKET, BY TYPE, 2024–2031 (USD MILLION) 168 TABLE 95 PLASMID DNA ISOLATION AND PURIFICATION MARKET, BY REGION, 2024–2031 (USD MILLION) 170 TABLE 96 NORTH AMERICA: PLASMID DNA ISOLATION AND PURIFICATION MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 170 TABLE 97 EUROPE: PLASMID DNA ISOLATION AND PURIFICATION MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 171 TABLE 98 ASIA PACIFIC: PLASMID DNA ISOLATION AND PURIFICATION MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 171 TABLE 99 LATIN AMERICA: PLASMID DNA ISOLATION AND PURIFICATION MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 172 TABLE 100 MIDDLE EAST: PLASMID DNA ISOLATION AND PURIFICATION MARKET, BY REGION, 2024–2031 (USD MILLION) 172 TABLE 101 GCC COUNTRIES: PLASMID DNA ISOLATION AND PURIFICATION MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 172 TABLE 102 TOTAL RNA ISOLATION AND PURIFICATION MARKET, BY REGION, 2024–2031 (USD MILLION) 173 TABLE 103 NORTH AMERICA: TOTAL RNA ISOLATION AND PURIFICATION MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 174 TABLE 104 EUROPE: TOTAL RNA ISOLATION AND PURIFICATION MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 174 TABLE 105 ASIA PACIFIC: TOTAL RNA ISOLATION AND PURIFICATION MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 175 TABLE 106 LATIN AMERICA: TOTAL RNA ISOLATION AND PURIFICATION MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 175 TABLE 107 MIDDLE EAST: TOTAL RNA ISOLATION AND PURIFICATION MARKET, BY REGION, 2024–2031 (USD MILLION) 176 TABLE 108 GCC COUNTRIES: TOTAL RNA ISOLATION AND PURIFICATION MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 176 TABLE 109 GENOMIC DNA ISOLATION AND PURIFICATION MARKET, BY REGION, 2024–2031 (USD MILLION) 177 TABLE 110 NORTH AMERICA: GENOMIC DNA ISOLATION AND PURIFICATION MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 178 TABLE 111 EUROPE: GENOMIC DNA ISOLATION AND PURIFICATION MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 178 TABLE 112 ASIA PACIFIC: GENOMIC DNA ISOLATION AND PURIFICATION MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 179 TABLE 113 LATIN AMERICA: GENOMIC DNA ISOLATION AND PURIFICATION MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 179 TABLE 114 MIDDLE EAST: GENOMIC DNA ISOLATION AND PURIFICATION MARKET, BY REGION, 2024–2031 (USD MILLION) 180 TABLE 115 GCC COUNTRIES: GENOMIC DNA ISOLATION AND PURIFICATION MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 180 TABLE 116 MESSENGER RNA ISOLATION AND PURIFICATION MARKET, BY REGION, 2024–2031 (USD MILLION) 181 TABLE 117 NORTH AMERICA: MESSENGER RNA ISOLATION AND PURIFICATION MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 181 TABLE 118 EUROPE: MESSENGER RNA ISOLATION AND PURIFICATION MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 182 TABLE 119 ASIA PACIFIC: MESSENGER RNA ISOLATION AND PURIFICATION MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 182 TABLE 120 LATIN AMERICA: MESSENGER RNA ISOLATION AND PURIFICATION MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 183 TABLE 121 MIDDLE EAST: MESSENGER RNA ISOLATION AND PURIFICATION MARKET, BY REGION, 2024–2031 (USD MILLION) 183 TABLE 122 GCC COUNTRIES: MESSENGER RNA ISOLATION AND PURIFICATION MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 183 TABLE 123 CIRCULATING NUCLEIC ACID ISOLATION AND PURIFICATION MARKET, BY REGION, 2024–2031 (USD MILLION) 184 TABLE 124 NORTH AMERICA: CIRCULATING NUCLEIC ACID ISOLATION AND PURIFICATION MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 185 TABLE 125 EUROPE: CIRCULATING NUCLEIC ACID ISOLATION AND PURIFICATION MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 185 TABLE 126 ASIA PACIFIC: CIRCULATING NUCLEIC ACID ISOLATION AND PURIFICATION MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 186 TABLE 127 LATIN AMERICA: CIRCULATING NUCLEIC ACID ISOLATION AND PURIFICATION MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 186 TABLE 128 MIDDLE EAST: CIRCULATING NUCLEIC ACID ISOLATION AND PURIFICATION MARKET, BY REGION, 2024–2031 (USD MILLION) 187 TABLE 129 GCC COUNTRIES: CIRCULATING NUCLEIC ACID ISOLATION AND PURIFICATION MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 187 TABLE 130 MICRORNA ISOLATION AND PURIFICATION MARKET, BY REGION, 2024–2031 (USD MILLION) 188 TABLE 131 NORTH AMERICA: MICRORNA ISOLATION AND PURIFICATION MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 188 TABLE 132 EUROPE: MICRORNA ISOLATION AND PURIFICATION MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 189 TABLE 133 ASIA PACIFIC: MICRORNA ISOLATION AND PURIFICATION MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 189 TABLE 134 LATIN AMERICA: MICRORNA ISOLATION AND PURIFICATION MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 190 TABLE 135 MIDDLE EAST: MICRORNA ISOLATION AND PURIFICATION MARKET, BY REGION, 2024–2031 (USD MILLION) 190 TABLE 136 GCC COUNTRIES: MICRORNA ISOLATION AND PURIFICATION MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 190 TABLE 137 OTHER NUCLEIC ACID ISOLATION AND PURIFICATION TYPES MARKET, BY REGION, 2024–2031 (USD MILLION) 191 TABLE 138 NORTH AMERICA: OTHER NUCLEIC ACID ISOLATION AND PURIFICATION TYPES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 192 TABLE 139 EUROPE: OTHER NUCLEIC ACID ISOLATION AND PURIFICATION TYPES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 192 TABLE 140 ASIA PACIFIC: OTHER NUCLEIC ACID ISOLATION AND PURIFICATION TYPES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 193 TABLE 141 LATIN AMERICA: OTHER NUCLEIC ACID ISOLATION AND PURIFICATION TYPES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 193 TABLE 142 MIDDLE EAST: OTHER NUCLEIC ACID ISOLATION AND PURIFICATION TYPES MARKET, BY REGION, 2024–2031 (USD MILLION) 194 TABLE 143 GCC COUNTRIES: OTHER NUCLEIC ACID ISOLATION AND PURIFICATION TYPES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 194 TABLE 144 NUCLEIC ACID ISOLATION AND PURIFICATION MARKET, BY SAMPLE TYPE, 2024–2031 (USD MILLION) 196 TABLE 145 NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR CELLULAR SAMPLES, BY TYPE, 2024–2031 (USD MILLION) 197 TABLE 146 NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR CELLULAR SAMPLES, BY REGION, 2024–2031 (USD MILLION) 198 TABLE 147 NORTH AMERICA: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR CELLULAR SAMPLES, BY COUNTRY, 2024–2031 (USD MILLION) 198 TABLE 148 EUROPE: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR CELLULAR SAMPLES, BY COUNTRY, 2024–2031 (USD MILLION) 199 TABLE 149 ASIA PACIFIC: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR CELLULAR SAMPLES, BY COUNTRY, 2024–2031 (USD MILLION) 199 TABLE 150 LATIN AMERICA: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR CELLULAR SAMPLES, BY COUNTRY, 2024–2031 (USD MILLION) 200 TABLE 151 MIDDLE EAST: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR CELLULAR SAMPLES, BY REGION, 2024–2031 (USD MILLION) 200 TABLE 152 GCC COUNTRIES: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR CELLULAR SAMPLES, BY COUNTRY, 2024–2031 (USD MILLION) 200 TABLE 153 NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR WBCS, BY REGION, 2024–2031 (USD MILLION) 201 TABLE 154 NORTH AMERICA: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR WBCS, BY COUNTRY, 2024–2031 (USD MILLION) 202 TABLE 155 EUROPE: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR WBCS, BY COUNTRY, 2024–2031 (USD MILLION) 202 TABLE 156 ASIA PACIFIC: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR WBCS, BY COUNTRY, 2024–2031 (USD MILLION) 203 TABLE 157 LATIN AMERICA: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR WBCS, BY COUNTRY, 2024–2031 (USD MILLION) 203 TABLE 158 MIDDLE EAST: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR WBCS, BY REGION, 2024–2031 (USD MILLION) 204 TABLE 159 GCC COUNTRIES: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR WBCS, BY COUNTRY, 2024–2031 (USD MILLION) 204 TABLE 160 NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR CULTURED CELLS, BY REGION, 2024–2031 (USD MILLION) 205 TABLE 161 NORTH AMERICA: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR CULTURED CELLS, BY COUNTRY, 2024–2031 (USD MILLION) 205 TABLE 162 EUROPE: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR CULTURED CELLS, BY COUNTRY, 2024–2031 (USD MILLION) 206 TABLE 163 ASIA PACIFIC: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR CULTURED CELLS, BY COUNTRY, 2024–2031 (USD MILLION) 206 TABLE 164 LATIN AMERICA: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR CULTURED CELLS, BY COUNTRY, 2024–2031 (USD MILLION) 207 TABLE 165 MIDDLE EAST: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR CULTURED CELLS, BY REGION, 2024–2031 (USD MILLION) 207 TABLE 166 GCC COUNTRIES: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR CULTURED CELLS, BY COUNTRY, 2024–2031 (USD MILLION) 207 TABLE 167 NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR BACTERIAL CELLS, BY REGION, 2024–2031 (USD MILLION) 208 TABLE 168 NORTH AMERICA: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR BACTERIAL CELLS, BY COUNTRY, 2024–2031 (USD MILLION) 209 TABLE 169 EUROPE: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR BACTERIAL CELLS, BY COUNTRY, 2024–2031 (USD MILLION) 209 TABLE 170 ASIA PACIFIC: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR BACTERIAL CELLS, BY COUNTRY, 2024–2031 (USD MILLION) 210 TABLE 171 LATIN AMERICA: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR BACTERIAL CELLS, BY COUNTRY, 2024–2031 (USD MILLION) 210 TABLE 172 MIDDLE EAST: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR BACTERIAL CELLS, BY REGION, 2024–2031 (USD MILLION) 211 TABLE 173 GCC COUNTRIES: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR BACTERIAL CELLS, BY COUNTRY, 2024–2031 (USD MILLION) 211 TABLE 174 NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR OTHER CELLULAR SAMPLES, BY REGION, 2024–2031 (USD MILLION) 212 TABLE 175 NORTH AMERICA: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR OTHER CELLULAR SAMPLES, BY COUNTRY, 2024–2031 (USD MILLION) 212 TABLE 176 EUROPE: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR OTHER CELLULAR SAMPLES, BY COUNTRY, 2024–2031 (USD MILLION) 213 TABLE 177 ASIA PACIFIC: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR OTHER CELLULAR SAMPLES, BY COUNTRY, 2024–2031 (USD MILLION) 213 TABLE 178 LATIN AMERICA: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR OTHER CELLULAR SAMPLES, BY COUNTRY, 2024–2031 (USD MILLION) 214 TABLE 179 MIDDLE EAST: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR OTHER CELLULAR SAMPLES, BY REGION, 2024–2031 (USD MILLION) 214 TABLE 180 GCC COUNTRIES: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR OTHER CELLULAR SAMPLES, BY COUNTRY, 2024–2031 (USD MILLION) 214 TABLE 181 NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR PRESERVED TISSUE SAMPLES, BY TYPE, 2024–2031 (USD MILLION) 215 TABLE 182 NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR PRESERVED TISSUE SAMPLES, BY REGION, 2024–2031 (USD MILLION) 216 TABLE 183 NORTH AMERICA: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR PRESERVED TISSUE SAMPLES, BY COUNTRY, 2024–2031 (USD MILLION) 216 TABLE 184 EUROPE: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR PRESERVED TISSUE SAMPLES, BY COUNTRY, 2024–2031 (USD MILLION) 217 TABLE 185 ASIA PACIFIC: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR PRESERVED TISSUE SAMPLES, BY COUNTRY, 2024–2031 (USD MILLION) 217 TABLE 186 LATIN AMERICA: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR PRESERVED TISSUE SAMPLES, BY COUNTRY, 2024–2031 (USD MILLION) 218 TABLE 187 MIDDLE EAST: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR PRESERVED TISSUE SAMPLES, BY REGION, 2024–2031 (USD MILLION) 218 TABLE 188 GCC COUNTRIES: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR PRESERVED TISSUE SAMPLES, BY COUNTRY, 2024–2031 (USD MILLION) 218 TABLE 189 NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR FRESH/FROZEN TISSUES, BY REGION, 2024–2031 (USD MILLION) 219 TABLE 190 NORTH AMERICA: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR FRESH/FROZEN TISSUES, BY COUNTRY, 2024–2031 (USD MILLION) 220 TABLE 191 EUROPE: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR FRESH/FROZEN TISSUES, BY COUNTRY, 2024–2031 (USD MILLION) 220 TABLE 192 ASIA PACIFIC: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR FRESH/FROZEN TISSUES, BY COUNTRY, 2024–2031 (USD MILLION) 221 TABLE 193 LATIN AMERICA: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR FRESH/FROZEN TISSUES, BY COUNTRY, 2024–2031 (USD MILLION) 221 TABLE 194 MIDDLE EAST: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR FRESH/FROZEN TISSUES, BY REGION, 2024–2031 (USD MILLION) 222 TABLE 195 GCC COUNTRIES: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR FRESH/FROZEN TISSUES, BY COUNTRY, 2024–2031 (USD MILLION) 222 TABLE 196 NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR FFPE, BY REGION, 2024–2031 (USD MILLION) 223 TABLE 197 NORTH AMERICA: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR FFPE, BY COUNTRY, 2024–2031 (USD MILLION) 223 TABLE 198 EUROPE: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR FFPE, BY COUNTRY, 2024–2031 (USD MILLION) 224 TABLE 199 ASIA PACIFIC: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR FFPE, BY COUNTRY, 2024–2031 (USD MILLION) 224 TABLE 200 LATIN AMERICA: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR FFPE, BY COUNTRY, 2024–2031 (USD MILLION) 225 TABLE 201 MIDDLE EAST: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR FFPE, BY REGION, 2024–2031 (USD MILLION) 225 TABLE 202 GCC COUNTRIES: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR FFPE, BY COUNTRY, 2024–2031 (USD MILLION) 225 TABLE 203 NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR OTHER PRESERVED TISSUE SAMPLES, BY REGION, 2024–2031 (USD MILLION) 226 TABLE 204 NORTH AMERICA: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR OTHER PRESERVED TISSUE SAMPLES, BY COUNTRY, 2024–2031 (USD MILLION) 227 TABLE 205 EUROPE: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR OTHER PRESERVED TISSUE SAMPLES, BY COUNTRY, 2024–2031 (USD MILLION) 227 TABLE 206 ASIA PACIFIC: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR OTHER PRESERVED TISSUE SAMPLES, BY COUNTRY, 2024–2031 (USD MILLION) 228 TABLE 207 LATIN AMERICA: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR OTHER PRESERVED TISSUE SAMPLES, BY COUNTRY, 2024–2031 (USD MILLION) 228 TABLE 208 MIDDLE EAST: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR OTHER PRESERVED TISSUE SAMPLES, BY REGION, 2024–2031 (USD MILLION) 229 TABLE 209 GCC COUNTRIES: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR OTHER PRESERVED TISSUE SAMPLES, BY COUNTRY, 2024–2031 (USD MILLION) 229 TABLE 210 NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR CELL-FREE SAMPLES, BY TYPE, 2024–2031 (USD MILLION) 230 TABLE 211 NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR CELL-FREE SAMPLES, BY REGION, 2024–2031 (USD MILLION) 230 TABLE 212 NORTH AMERICA: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR CELL-FREE SAMPLES, BY COUNTRY, 2024–2031 (USD MILLION) 231 TABLE 213 EUROPE: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR CELL-FREE SAMPLES, BY COUNTRY, 2024–2031 (USD MILLION) 231 TABLE 214 ASIA PACIFIC: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR CELL-FREE SAMPLES, BY COUNTRY, 2024–2031 (USD MILLION) 232 TABLE 215 LATIN AMERICA: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR CELL-FREE SAMPLES, BY COUNTRY, 2024–2031 (USD MILLION) 232 TABLE 216 MIDDLE EAST: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR CELL-FREE SAMPLES, BY REGION, 2024–2031 (USD MILLION) 233 TABLE 217 GCC COUNTRIES: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR CELL-FREE SAMPLES, BY COUNTRY, 2024–2031 (USD MILLION) 233 TABLE 218 NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR CFDNA/CTDNA, BY REGION, 2024–2031 (USD MILLION) 234 TABLE 219 NORTH AMERICA: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR CFDNA/CTDNA, BY COUNTRY, 2024–2031 (USD MILLION) 234 TABLE 220 EUROPE: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR CFDNA/CTDNA, BY COUNTRY, 2024–2031 (USD MILLION) 235 TABLE 221 ASIA PACIFIC: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR CFDNA/CTDNA, BY COUNTRY, 2024–2031 (USD MILLION) 235 TABLE 222 LATIN AMERICA: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR CFDNA/CTDNA, BY COUNTRY, 2024–2031 (USD MILLION) 236 TABLE 223 MIDDLE EAST: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR CFDNA/CTDNA, BY REGION, 2024–2031 (USD MILLION) 236 TABLE 224 GCC COUNTRIES: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR CFDNA/CTDNA, BY COUNTRY, 2024–2031 (USD MILLION) 236 TABLE 225 NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR OTHER CELL-FREE SAMPLES, BY REGION, 2024–2031 (USD MILLION) 237 TABLE 226 NORTH AMERICA: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR OTHER CELL-FREE SAMPLES, BY COUNTRY, 2024–2031 (USD MILLION) 238 TABLE 227 EUROPE: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR OTHER CELL-FREE SAMPLES, BY COUNTRY, 2024–2031 (USD MILLION) 238 TABLE 228 ASIA PACIFIC: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR OTHER CELL-FREE SAMPLES, BY COUNTRY, 2024–2031 (USD MILLION) 239 TABLE 229 LATIN AMERICA: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR OTHER CELL-FREE SAMPLES, BY COUNTRY, 2024–2031 (USD MILLION) 239 TABLE 230 MIDDLE EAST: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR OTHER CELL-FREE SAMPLES, BY REGION, 2024–2031 (USD MILLION) 240 TABLE 231 GCC COUNTRIES: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR OTHER CELL-FREE SAMPLES, BY COUNTRY, 2024–2031 (USD MILLION) 240 TABLE 232 NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR OTHER SAMPLES, BY REGION, 2024–2031 (USD MILLION) 241 TABLE 233 NORTH AMERICA: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR OTHER SAMPLES, BY COUNTRY, 2024–2031 (USD MILLION) 241 TABLE 234 EUROPE: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR OTHER SAMPLES, BY COUNTRY, 2024–2031 (USD MILLION) 242 TABLE 235 ASIA PACIFIC: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR OTHER SAMPLES, BY COUNTRY, 2024–2031 (USD MILLION) 242 TABLE 236 LATIN AMERICA: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR OTHER SAMPLES, BY COUNTRY, 2024–2031 (USD MILLION) 243 TABLE 237 MIDDLE EAST: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR OTHER SAMPLES, BY REGION, 2024–2031 (USD MILLION) 243   TABLE 238 GCC COUNTRIES: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR OTHER SAMPLES, BY COUNTRY, 2024–2031 (USD MILLION) 243 TABLE 239 NUCLEIC ACID ISOLATION AND PURIFICATION MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 245 TABLE 240 NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR DIAGNOSTIC APPLICATIONS, BY REGION, 2024–2031 (USD MILLION) 246 TABLE 241 NORTH AMERICA: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR DIAGNOSTIC APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION) 246 TABLE 242 EUROPE: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR DIAGNOSTIC APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION) 247 TABLE 243 ASIA PACIFIC: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR DIAGNOSTIC APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION) 247 TABLE 244 LATIN AMERICA: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR DIAGNOSTIC APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION) 248 TABLE 245 MIDDLE EAST: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR DIAGNOSTIC APPLICATIONS, BY REGION, 2024–2031 (USD MILLION) 248 TABLE 246 GCC COUNTRIES: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR DIAGNOSTIC APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION) 248 TABLE 247 NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR DRUG DISCOVERY & DEVELOPMENT APPLICATIONS, BY REGION, 2024–2031 (USD MILLION) 250 TABLE 248 NORTH AMERICA: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR DRUG DISCOVERY & DEVELOPMENT APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION) 250 TABLE 249 EUROPE: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR DRUG DISCOVERY & DEVELOPMENT APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION) 251 TABLE 250 ASIA PACIFIC: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR DRUG DISCOVERY & DEVELOPMENT APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION) 251 TABLE 251 LATIN AMERICA: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR DRUG DISCOVERY & DEVELOPMENT APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION) 252 TABLE 252 MIDDLE EAST: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR DRUG DISCOVERY & DEVELOPMENT APPLICATIONS, BY REGION, 2024–2031 (USD MILLION) 252 TABLE 253 GCC COUNTRIES: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR DRUG DISCOVERY & DEVELOPMENT APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION) 252 TABLE 254 NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR PERSONALIZED MEDICINE APPLICATIONS, BY REGION, 2024–2031 (USD MILLION) 254 TABLE 255 NORTH AMERICA: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR PERSONALIZED MEDICINE APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION) 254 TABLE 256 EUROPE: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR PERSONALIZED MEDICINE APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION) 255 TABLE 257 ASIA PACIFIC: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR PERSONALIZED MEDICINE APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION) 255 TABLE 258 LATIN AMERICA: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR PERSONALIZED MEDICINE APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION) 256 TABLE 259 MIDDLE EAST: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR PERSONALIZED MEDICINE APPLICATIONS, BY REGION, 2024–2031 (USD MILLION) 256 TABLE 260 GCC COUNTRIES: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR PERSONALIZED MEDICINE APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION) 256 TABLE 261 NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR AGRICULTURE & ANIMAL RESEARCH APPLICATIONS, BY REGION, 2024–2031 (USD MILLION) 258 TABLE 262 NORTH AMERICA: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR AGRICULTURE & ANIMAL RESEARCH APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION) 258 TABLE 263 EUROPE: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR AGRICULTURE & ANIMAL RESEARCH APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION) 259 TABLE 264 ASIA PACIFIC: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR AGRICULTURE & ANIMAL RESEARCH APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION) 259 TABLE 265 LATIN AMERICA: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR AGRICULTURE & ANIMAL RESEARCH APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION) 260 TABLE 266 MIDDLE EAST: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR AGRICULTURE & ANIMAL RESEARCH APPLICATIONS, BY REGION, 2024–2031 (USD MILLION) 260 TABLE 267 GCC COUNTRIES: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR AGRICULTURE & ANIMAL RESEARCH APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION) 260 TABLE 268 NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR OTHER APPLICATIONS, BY REGION, 2024–2031 (USD MILLION) 261 TABLE 269 NORTH AMERICA: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION) 262 TABLE 270 EUROPE: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION) 262 TABLE 271 ASIA PACIFIC: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION) 263 TABLE 272 LATIN AMERICA: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION) 263 TABLE 273 MIDDLE EAST: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR OTHER APPLICATIONS, BY REGION, 2024–2031 (USD MILLION) 264 TABLE 274 GCC COUNTRIES: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION) 264 TABLE 275 NUCLEIC ACID ISOLATION AND PURIFICATION MARKET, BY END USER, 2024–2031 (USD MILLION) 266 TABLE 276 NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR HOSPITALS & DIAGNOSTIC CENTERS, BY REGION, 2024–2031 (USD MILLION) 268 TABLE 277 NORTH AMERICA: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR HOSPITALS & DIAGNOSTIC CENTERS, BY COUNTRY, 2024–2031 (USD MILLION) 268 TABLE 278 EUROPE: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR HOSPITALS & DIAGNOSTIC CENTERS, BY COUNTRY, 2024–2031 (USD MILLION) 269 TABLE 279 ASIA PACIFIC: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR HOSPITALS & DIAGNOSTIC CENTERS, BY COUNTRY, 2024–2031 (USD MILLION) 269 TABLE 280 LATIN AMERICA: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR HOSPITALS & DIAGNOSTIC CENTERS, BY COUNTRY, 2024–2031 (USD MILLION) 270   TABLE 281 MIDDLE EAST: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR HOSPITALS & DIAGNOSTIC CENTERS, BY REGION, 2024–2031 (USD MILLION) 270 TABLE 282 GCC COUNTRIES: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR HOSPITALS & DIAGNOSTIC CENTERS, BY COUNTRY, 2024–2031 (USD MILLION) 270 TABLE 283 NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR ACADEMIC & GOVERNMENT RESEARCH INSTITUTES, BY REGION, 2024–2031 (USD MILLION) 272 TABLE 284 NORTH AMERICA: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR ACADEMIC & GOVERNMENT RESEARCH INSTITUTES, BY COUNTRY, 2024–2031 (USD MILLION) 272 TABLE 285 EUROPE: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR ACADEMIC & GOVERNMENT RESEARCH INSTITUTES, BY COUNTRY, 2024–2031 (USD MILLION) 273 TABLE 286 ASIA PACIFIC: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR ACADEMIC & GOVERNMENT RESEARCH INSTITUTES, BY COUNTRY, 2024–2031 (USD MILLION) 273 TABLE 287 LATIN AMERICA: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR ACADEMIC & GOVERNMENT RESEARCH INSTITUTES, BY COUNTRY, 2024–2031 (USD MILLION) 274 TABLE 288 MIDDLE EAST: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR ACADEMIC & GOVERNMENT RESEARCH INSTITUTES, BY REGION, 2024–2031 (USD MILLION) 274 TABLE 289 GCC COUNTRIES: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR ACADEMIC & GOVERNMENT RESEARCH INSTITUTES, BY COUNTRY, 2024–2031 (USD MILLION) 274 TABLE 290 NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2024–2031 (USD MILLION) 276 TABLE 291 NORTH AMERICA: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2024–2031 (USD MILLION) 276 TABLE 292 EUROPE: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2024–2031 (USD MILLION) 277 TABLE 293 ASIA PACIFIC: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2024–2031 (USD MILLION) 277 TABLE 294 LATIN AMERICA: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2024–2031 (USD MILLION) 278 TABLE 295 MIDDLE EAST: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2024–2031 (USD MILLION) 278 TABLE 296 GCC COUNTRIES: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2024–2031 (USD MILLION) 279 TABLE 297 NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2024–2031 (USD MILLION) 280 TABLE 298 NORTH AMERICA: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2024–2031 (USD MILLION) 280 TABLE 299 EUROPE: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2024–2031 (USD MILLION) 281 TABLE 300 ASIA PACIFIC: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2024–2031 (USD MILLION) 281 TABLE 301 LATIN AMERICA: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2024–2031 (USD MILLION) 282 TABLE 302 MIDDLE EAST: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2024–2031 (USD MILLION) 282 TABLE 303 GCC COUNTRIES: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2024–2031 (USD MILLION) 282 TABLE 304 NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR OTHER END USERS, BY REGION, 2024–2031 (USD MILLION) 283 TABLE 305 NORTH AMERICA: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR OTHER END USERS, BY COUNTRY, 2024–2031 (USD MILLION) 284 TABLE 306 EUROPE: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR OTHER END USERS, BY COUNTRY, 2024–2031 (USD MILLION) 284 TABLE 307 ASIA PACIFIC: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR OTHER END USERS, BY COUNTRY, 2024–2031 (USD MILLION) 285 TABLE 308 LATIN AMERICA: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR OTHER END USERS, BY COUNTRY, 2024–2031 (USD MILLION) 285 TABLE 309 MIDDLE EAST: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR OTHER END USERS, BY REGION, 2024–2031 (USD MILLION) 286 TABLE 310 GCC COUNTRIES: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR OTHER END USERS, BY COUNTRY, 2024–2031 (USD MILLION) 286 TABLE 311 NUCLEIC ACID ISOLATION AND PURIFICATION MARKET, BY REGION, 2024–2031 (USD MILLION) 288 TABLE 312 NORTH AMERICA: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 289 TABLE 313 NORTH AMERICA: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 290 TABLE 314 NORTH AMERICA: NUCLEIC ACID ISOLATION AND PURIFICATION INSTRUMENTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 290 TABLE 315 NORTH AMERICA: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET, BY METHOD, 2024–2031 (USD MILLION) 291 TABLE 316 NORTH AMERICA: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET, BY TYPE, 2024–2031 (USD MILLION) 292 TABLE 317 NORTH AMERICA: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET, BY SAMPLE TYPE, 2024–2031 (USD MILLION) 292 TABLE 318 NORTH AMERICA: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR CELLULAR SAMPLES, BY TYPE, 2024–2031 (USD MILLION) 293 TABLE 319 NORTH AMERICA: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR PRESERVED TISSUE SAMPLES, BY TYPE, 2024–2031 (USD MILLION) 293 TABLE 320 NORTH AMERICA: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR CELL-FREE SAMPLES, BY TYPE, 2024–2031 (USD MILLION) 294 TABLE 321 NORTH AMERICA: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 294 TABLE 322 NORTH AMERICA: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET, BY END USER, 2024–2031 (USD MILLION) 295 TABLE 323 US: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 296 TABLE 324 US: NUCLEIC ACID ISOLATION AND PURIFICATION INSTRUMENTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 296 TABLE 325 US: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET, BY METHOD, 2024–2031 (USD MILLION) 297 TABLE 326 US: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET, BY TYPE, 2024–2031 (USD MILLION) 298 TABLE 327 US: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET, BY SAMPLE TYPE, 2024–2031 (USD MILLION) 298 TABLE 328 US: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR CELLULAR SAMPLES, BY TYPE, 2024–2031 (USD MILLION) 299 TABLE 329 US: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR PRESERVED TISSUE SAMPLES, BY TYPE, 2024–2031 (USD MILLION) 299 TABLE 330 US: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR CELL-FREE SAMPLES, BY TYPE, 2024–2031 (USD MILLION) 300 TABLE 331 US: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 300 TABLE 332 US: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET, BY END USER, 2024–2031 (USD MILLION) 301 TABLE 333 CANADA: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 302 TABLE 334 CANADA: NUCLEIC ACID ISOLATION AND PURIFICATION INSTRUMENTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 302 TABLE 335 CANADA: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET, BY METHOD, 2024–2031 (USD MILLION) 302 TABLE 336 CANADA: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET, BY TYPE, 2024–2031 (USD MILLION) 303 TABLE 337 CANADA: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET, BY SAMPLE TYPE, 2024–2031 (USD MILLION) 303 TABLE 338 CANADA: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR CELLULAR SAMPLES, BY TYPE, 2024–2031 (USD MILLION) 304 TABLE 339 CANADA: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR PRESERVED TISSUE SAMPLES, BY TYPE, 2024–2031 (USD MILLION) 304 TABLE 340 CANADA: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR CELL-FREE SAMPLES, BY TYPE, 2024–2031 (USD MILLION) 304 TABLE 341 CANADA: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 305 TABLE 342 CANADA: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET, BY END USER, 2024–2031 (USD MILLION) 305 TABLE 343 EUROPE: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 306 TABLE 344 EUROPE: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 307 TABLE 345 EUROPE: NUCLEIC ACID ISOLATION AND PURIFICATION INSTRUMENTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 307 TABLE 346 EUROPE: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET, BY METHOD, 2024–2031 (USD MILLION) 308 TABLE 347 EUROPE: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET, BY TYPE, 2024–2031 (USD MILLION) 309 TABLE 348 EUROPE: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET, BY SAMPLE TYPE, 2024–2031 (USD MILLION) 310 TABLE 349 EUROPE: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR CELLULAR SAMPLES, BY TYPE, 2024–2031 (USD MILLION) 310 TABLE 350 EUROPE: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR PRESERVED TISSUE SAMPLES, BY TYPE, 2024–2031 (USD MILLION) 311 TABLE 351 EUROPE: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR CELL-FREE SAMPLES, BY TYPE, 2024–2031 (USD MILLION) 311 TABLE 352 EUROPE: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 312 TABLE 353 EUROPE: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET, BY END USER, 2024–2031 (USD MILLION) 312 TABLE 354 GERMANY: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 313 TABLE 355 GERMANY: NUCLEIC ACID ISOLATION AND PURIFICATION INSTRUMENTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 313 TABLE 356 GERMANY: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET, BY METHOD, 2024–2031 (USD MILLION) 314 TABLE 357 GERMANY: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET, BY TYPE, 2024–2031 (USD MILLION) 314 TABLE 358 GERMANY: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET, BY SAMPLE TYPE, 2024–2031 (USD MILLION) 315 TABLE 359 GERMANY: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR CELLULAR SAMPLES, BY TYPE, 2024–2031 (USD MILLION) 315 TABLE 360 GERMANY: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR PRESERVED TISSUE SAMPLES, BY TYPE, 2024–2031 (USD MILLION) 316 TABLE 361 GERMANY: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR CELL-FREE SAMPLES, BY TYPE, 2024–2031 (USD MILLION) 316 TABLE 362 GERMANY: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 317 TABLE 363 GERMANY: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET, BY END USER, 2024–2031 (USD MILLION) 317 TABLE 364 UK: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 318 TABLE 365 UK: NUCLEIC ACID ISOLATION AND PURIFICATION INSTRUMENTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 318 TABLE 366 UK: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET, BY METHOD, 2024–2031 (USD MILLION) 319 TABLE 367 UK: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET, BY TYPE, 2024–2031 (USD MILLION) 319 TABLE 368 UK: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET, BY SAMPLE TYPE, 2024–2031 (USD MILLION) 320 TABLE 369 UK: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR CELLULAR SAMPLES, BY TYPE, 2024–2031 (USD MILLION) 320 TABLE 370 UK: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR PRESERVED TISSUE SAMPLES, BY TYPE, 2024–2031 (USD MILLION) 320 TABLE 371 UK: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR CELL-FREE SAMPLES, BY TYPE, 2024–2031 (USD MILLION) 321 TABLE 372 UK: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 321 TABLE 373 UK: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET, BY END USER, 2024–2031 (USD MILLION) 322 TABLE 374 FRANCE: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 323 TABLE 375 FRANCE: NUCLEIC ACID ISOLATION AND PURIFICATION INSTRUMENTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 323 TABLE 376 FRANCE: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET, BY METHOD, 2024–2031 (USD MILLION) 323 TABLE 377 FRANCE: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET, BY TYPE, 2024–2031 (USD MILLION) 324 TABLE 378 FRANCE: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET, BY SAMPLE TYPE, 2024–2031 (USD MILLION) 324 TABLE 379 FRANCE: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR CELLULAR SAMPLES, BY TYPE, 2024–2031 (USD MILLION) 325 TABLE 380 FRANCE: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR PRESERVED TISSUE SAMPLES, BY TYPE, 2024–2031 (USD MILLION) 325 TABLE 381 FRANCE: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR CELL-FREE SAMPLES, BY TYPE, 2024–2031 (USD MILLION) 325 TABLE 382 FRANCE: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 326 TABLE 383 FRANCE: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET, BY END USER, 2024–2031 (USD MILLION) 326 TABLE 384 ITALY: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 327 TABLE 385 ITALY: NUCLEIC ACID ISOLATION AND PURIFICATION INSTRUMENTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 327 TABLE 386 ITALY: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET, BY METHOD, 2024–2031 (USD MILLION) 328 TABLE 387 ITALY: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET, BY TYPE, 2024–2031 (USD MILLION) 328 TABLE 388 ITALY: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET, BY SAMPLE TYPE, 2024–2031 (USD MILLION) 329 TABLE 389 ITALY: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR CELLULAR SAMPLES, BY TYPE, 2024–2031 (USD MILLION) 329 TABLE 390 ITALY: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR PRESERVED TISSUE SAMPLES, BY TYPE, 2024–2031 (USD MILLION) 329 TABLE 391 ITALY: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR CELL-FREE SAMPLES, BY TYPE, 2024–2031 (USD MILLION) 330 TABLE 392 ITALY: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 330 TABLE 393 ITALY: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET, BY END USER, 2024–2031 (USD MILLION) 331 TABLE 394 SPAIN: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 332 TABLE 395 SPAIN: NUCLEIC ACID ISOLATION AND PURIFICATION INSTRUMENTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 332 TABLE 396 SPAIN: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET, BY METHOD, 2024–2031 (USD MILLION) 332 TABLE 397 SPAIN: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET, BY TYPE, 2024–2031 (USD MILLION) 333 TABLE 398 SPAIN: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET, BY SAMPLE TYPE, 2024–2031 (USD MILLION) 333 TABLE 399 SPAIN: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR CELLULAR SAMPLES, BY TYPE, 2024–2031 (USD MILLION) 334 TABLE 400 SPAIN: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR PRESERVED TISSUE SAMPLES, BY TYPE, 2024–2031 (USD MILLION) 334 TABLE 401 SPAIN: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR CELL-FREE SAMPLES, BY TYPE, 2024–2031 (USD MILLION) 334 TABLE 402 SPAIN: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 335 TABLE 403 SPAIN: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET, BY END USER, 2024–2031 (USD MILLION) 335 TABLE 404 REST OF EUROPE: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 336 TABLE 405 REST OF EUROPE: NUCLEIC ACID ISOLATION AND PURIFICATION INSTRUMENTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 336 TABLE 406 REST OF EUROPE: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET, BY METHOD, 2024–2031 (USD MILLION) 337 TABLE 407 REST OF EUROPE: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET, BY TYPE, 2024–2031 (USD MILLION) 337 TABLE 408 REST OF EUROPE: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET, BY SAMPLE TYPE, 2024–2031 (USD MILLION) 338 TABLE 409 REST OF EUROPE: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR CELLULAR SAMPLES, BY TYPE, 2024–2031 (USD MILLION) 338 TABLE 410 REST OF EUROPE: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR PRESERVED TISSUE SAMPLES, BY TYPE, 2024–2031 (USD MILLION) 339 TABLE 411 REST OF EUROPE: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR CELL-FREE SAMPLES, BY TYPE, 2024–2031 (USD MILLION) 339 TABLE 412 REST OF EUROPE: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 339 TABLE 413 REST OF EUROPE: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET, BY END USER, 2024–2031 (USD MILLION) 340 TABLE 414 ASIA PACIFIC: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 342 TABLE 415 ASIA PACIFIC: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 342 TABLE 416 ASIA PACIFIC: NUCLEIC ACID ISOLATION AND PURIFICATION INSTRUMENTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 343 TABLE 417 ASIA PACIFIC: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET, BY METHOD, 2024–2031 (USD MILLION) 343 TABLE 418 ASIA PACIFIC: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET, BY TYPE, 2024–2031 (USD MILLION) 344 TABLE 419 ASIA PACIFIC: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET, BY SAMPLE TYPE, 2024–2031 (USD MILLION) 345 TABLE 420 ASIA PACIFIC: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR CELLULAR SAMPLES, BY TYPE, 2024–2031 (USD MILLION) 345 TABLE 421 ASIA PACIFIC: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR PRESERVED TISSUE SAMPLES, BY TYPE, 2024–2031 (USD MILLION) 346 TABLE 422 ASIA PACIFIC: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR CELL-FREE SAMPLES, BY TYPE, 2024–2031 (USD MILLION) 346 TABLE 423 ASIA PACIFIC: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 347 TABLE 424 ASIA PACIFIC: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET, BY END USER, 2024–2031 (USD MILLION) 347 TABLE 425 CHINA: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 348 TABLE 426 CHINA: NUCLEIC ACID ISOLATION AND PURIFICATION INSTRUMENTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 349 TABLE 427 CHINA: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET, BY METHOD, 2024–2031 (USD MILLION) 349 TABLE 428 CHINA: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET, BY TYPE, 2024–2031 (USD MILLION) 350 TABLE 429 CHINA: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET, BY SAMPLE TYPE, 2024–2031 (USD MILLION) 350 TABLE 430 CHINA: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR CELLULAR SAMPLES, BY TYPE, 2024–2031 (USD MILLION) 351 TABLE 431 CHINA: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR PRESERVED TISSUE SAMPLES, BY TYPE, 2024–2031 (USD MILLION) 351 TABLE 432 CHINA: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR CELL-FREE SAMPLES, BY TYPE, 2024–2031 (USD MILLION) 351 TABLE 433 CHINA: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 352 TABLE 434 CHINA: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET, BY END USER, 2024–2031 (USD MILLION) 352 TABLE 435 JAPAN: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 353 TABLE 436 JAPAN: NUCLEIC ACID ISOLATION AND PURIFICATION INSTRUMENTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 353 TABLE 437 JAPAN: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET, BY METHOD, 2024–2031 (USD MILLION) 354 TABLE 438 JAPAN: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET, BY TYPE, 2024–2031 (USD MILLION) 354 TABLE 439 JAPAN: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET, BY SAMPLE TYPE, 2024–2031 (USD MILLION) 355 TABLE 440 JAPAN: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR CELLULAR SAMPLES, BY TYPE, 2024–2031 (USD MILLION) 355 TABLE 441 JAPAN: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR PRESERVED TISSUE SAMPLES, BY TYPE, 2024–2031 (USD MILLION) 355 TABLE 442 JAPAN: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR CELL-FREE SAMPLES, BY TYPE, 2024–2031 (USD MILLION) 356 TABLE 443 JAPAN: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 356 TABLE 444 JAPAN: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET, BY END USER, 2024–2031 (USD MILLION) 357 TABLE 445 INDIA: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 358 TABLE 446 INDIA: NUCLEIC ACID ISOLATION AND PURIFICATION INSTRUMENTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 358 TABLE 447 INDIA: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET, BY METHOD, 2024–2031 (USD MILLION) 358 TABLE 448 INDIA: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET, BY TYPE, 2024–2031 (USD MILLION) 359 TABLE 449 INDIA: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET, BY SAMPLE TYPE, 2024–2031 (USD MILLION) 359 TABLE 450 INDIA: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR CELLULAR SAMPLES, BY TYPE, 2024–2031 (USD MILLION) 360 TABLE 451 INDIA: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR PRESERVED TISSUE SAMPLES, BY TYPE, 2024–2031 (USD MILLION) 360 TABLE 452 INDIA: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR CELL-FREE SAMPLES, BY TYPE, 2024–2031 (USD MILLION) 360 TABLE 453 INDIA: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 361 TABLE 454 INDIA: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET, BY END USER, 2024–2031 (USD MILLION) 361 TABLE 455 AUSTRALIA: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 362 TABLE 456 AUSTRALIA: NUCLEIC ACID ISOLATION AND PURIFICATION INSTRUMENTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 362 TABLE 457 AUSTRALIA: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET, BY METHOD, 2024–2031 (USD MILLION) 363 TABLE 458 AUSTRALIA: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET, BY TYPE, 2024–2031 (USD MILLION) 363 TABLE 459 AUSTRALIA: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET, BY SAMPLE TYPE, 2024–2031 (USD MILLION) 364 TABLE 460 AUSTRALIA: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR CELLULAR SAMPLES, BY TYPE, 2024–2031 (USD MILLION) 364 TABLE 461 AUSTRALIA: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR PRESERVED TISSUE SAMPLES, BY TYPE, 2024–2031 (USD MILLION) 364 TABLE 462 AUSTRALIA: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR CELL-FREE SAMPLES, BY TYPE, 2024–2031 (USD MILLION) 365 TABLE 463 AUSTRALIA: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 365 TABLE 464 AUSTRALIA: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET, BY END USER, 2024–2031 (USD MILLION) 365 TABLE 465 SOUTH KOREA: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 366 TABLE 466 SOUTH KOREA: NUCLEIC ACID ISOLATION AND PURIFICATION INSTRUMENTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 367 TABLE 467 SOUTH KOREA: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET, BY METHOD, 2024–2031 (USD MILLION) 367 TABLE 468 SOUTH KOREA: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET, BY TYPE, 2024–2031 (USD MILLION) 368 TABLE 469 SOUTH KOREA: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET, BY SAMPLE TYPE, 2024–2031 (USD MILLION) 368 TABLE 470 SOUTH KOREA: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR CELLULAR SAMPLES, BY TYPE, 2024–2031 (USD MILLION) 369 TABLE 471 SOUTH KOREA: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR PRESERVED TISSUE SAMPLES, BY TYPE, 2024–2031 (USD MILLION) 369 TABLE 472 SOUTH KOREA: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR CELL-FREE SAMPLES, BY TYPE, 2024–2031 (USD MILLION) 369 TABLE 473 SOUTH KOREA: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 370 TABLE 474 SOUTH KOREA: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET, BY END USER, 2024–2031 (USD MILLION) 370 TABLE 475 REST OF ASIA PACIFIC: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 371 TABLE 476 REST OF ASIA PACIFIC: NUCLEIC ACID ISOLATION AND PURIFICATION INSTRUMENTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 371 TABLE 477 REST OF ASIA PACIFIC: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET, BY METHOD, 2024–2031 (USD MILLION) 372 TABLE 478 REST OF ASIA PACIFIC: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET, BY TYPE, 2024–2031 (USD MILLION) 372 TABLE 479 REST OF ASIA PACIFIC: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET, BY SAMPLE TYPE, 2024–2031 (USD MILLION) 373 TABLE 480 REST OF ASIA PACIFIC: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR CELLULAR SAMPLES, BY TYPE, 2024–2031 (USD MILLION) 373 TABLE 481 REST OF ASIA PACIFIC: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR PRESERVED TISSUE SAMPLES, BY TYPE, 2024–2031 (USD MILLION) 373 TABLE 482 REST OF ASIA PACIFIC: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR CELL-FREE SAMPLES, BY TYPE, 2024–2031 (USD MILLION) 374 TABLE 483 REST OF ASIA PACIFIC: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 374 TABLE 484 REST OF ASIA PACIFIC: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET, BY END USER, 2024–2031 (USD MILLION) 374 TABLE 485 LATIN AMERICA: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 375 TABLE 486 LATIN AMERICA: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 376 TABLE 487 LATIN AMERICA: NUCLEIC ACID ISOLATION AND PURIFICATION INSTRUMENTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 376 TABLE 488 LATIN AMERICA: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET, BY METHOD, 2024–2031 (USD MILLION) 376 TABLE 489 LATIN AMERICA: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET, BY TYPE, 2024–2031 (USD MILLION) 377 TABLE 490 LATIN AMERICA: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET, BY SAMPLE TYPE, 2024–2031 (USD MILLION) 377 TABLE 491 LATIN AMERICA: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR CELLULAR SAMPLES, BY TYPE, 2024–2031 (USD MILLION) 378 TABLE 492 LATIN AMERICA: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR PRESERVED TISSUE SAMPLES, BY TYPE, 2024–2031 (USD MILLION) 378 TABLE 493 LATIN AMERICA: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR CELL-FREE SAMPLES, BY TYPE, 2024–2031 (USD MILLION) 378 TABLE 494 LATIN AMERICA: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 379 TABLE 495 LATIN AMERICA: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET, BY END USER, 2024–2031 (USD MILLION) 379 TABLE 496 BRAZIL: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 380 TABLE 497 BRAZIL: NUCLEIC ACID ISOLATION AND PURIFICATION INSTRUMENTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 380 TABLE 498 BRAZIL: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET, BY METHOD, 2024–2031 (USD MILLION) 381 TABLE 499 BRAZIL: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET, BY TYPE, 2024–2031 (USD MILLION) 381 TABLE 500 BRAZIL: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET, BY SAMPLE TYPE, 2024–2031 (USD MILLION) 382 TABLE 501 BRAZIL: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR CELLULAR SAMPLES, BY TYPE, 2024–2031 (USD MILLION) 382 TABLE 502 BRAZIL: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR PRESERVED TISSUE SAMPLES, BY TYPE, 2024–2031 (USD MILLION) 382 TABLE 503 BRAZIL: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR CELL-FREE SAMPLES, BY TYPE, 2024–2031 (USD MILLION) 383 TABLE 504 BRAZIL: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 383 TABLE 505 BRAZIL: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET, BY END USER, 2024–2031 (USD MILLION) 384 TABLE 506 MEXICO: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 385 TABLE 507 MEXICO: NUCLEIC ACID ISOLATION AND PURIFICATION INSTRUMENTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 385 TABLE 508 MEXICO: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET, BY METHOD, 2024–2031 (USD MILLION) 385 TABLE 509 MEXICO: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET, BY TYPE, 2024–2031 (USD MILLION) 386 TABLE 510 MEXICO: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET, BY SAMPLE TYPE, 2024–2031 (USD MILLION) 386 TABLE 511 MEXICO: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR CELLULAR SAMPLES, BY TYPE, 2024–2031 (USD MILLION) 387 TABLE 512 MEXICO: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR PRESERVED TISSUE SAMPLES, BY TYPE, 2024–2031 (USD MILLION) 387 TABLE 513 MEXICO: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR CELL-FREE SAMPLES, BY TYPE, 2024–2031 (USD MILLION) 387 TABLE 514 MEXICO: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 388 TABLE 515 MEXICO: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET, BY END USER, 2024–2031 (USD MILLION) 388 TABLE 516 REST OF LATIN AMERICA: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 389 TABLE 517 REST OF LATIN AMERICA: NUCLEIC ACID ISOLATION AND PURIFICATION INSTRUMENTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 389 TABLE 518 REST OF LATIN AMERICA: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET, BY METHOD, 2024–2031 (USD MILLION) 390 TABLE 519 REST OF LATIN AMERICA: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET, BY TYPE, 2024–2031 (USD MILLION) 390 TABLE 520 REST OF LATIN AMERICA: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET, BY SAMPLE TYPE, 2024–2031 (USD MILLION) 391 TABLE 521 REST OF LATIN AMERICA: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR CELLULAR SAMPLES, BY TYPE, 2024–2031 (USD MILLION) 391 TABLE 522 REST OF LATIN AMERICA: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR PRESERVED TISSUE SAMPLES, BY TYPE, 2024–2031 (USD MILLION) 391 TABLE 523 REST OF LATIN AMERICA: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR CELL-FREE SAMPLES, BY TYPE, 2024–2031 (USD MILLION) 392 TABLE 524 REST OF LATIN AMERICA: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 392 TABLE 525 REST OF LATIN AMERICA: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET, BY END USER, 2024–2031 (USD MILLION) 393 TABLE 526 MIDDLE EAST: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET, BY REGION, 2024–2031 (USD MILLION) 393 TABLE 527 MIDDLE EAST: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 394 TABLE 528 MIDDLE EAST: NUCLEIC ACID ISOLATION AND PURIFICATION INSTRUMENTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 394 TABLE 529 MIDDLE EAST: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET, BY METHOD, 2024–2031 (USD MILLION) 394 TABLE 530 MIDDLE EAST: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET, BY TYPE, 2024–2031 (USD MILLION) 395 TABLE 531 MIDDLE EAST: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET, BY SAMPLE TYPE, 2024–2031 (USD MILLION) 395 TABLE 532 MIDDLE EAST: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR CELLULAR SAMPLES, BY TYPE, 2024–2031 (USD MILLION) 396 TABLE 533 MIDDLE EAST: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR PRESERVED TISSUE SAMPLES, BY TYPE, 2024–2031 (USD MILLION) 396 TABLE 534 MIDDLE EAST: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR CELL-FREE SAMPLES, BY TYPE, 2024–2031 (USD MILLION) 396 TABLE 535 MIDDLE EAST: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 397 TABLE 536 MIDDLE EAST: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET, BY END USER, 2024–2031 (USD MILLION) 397 TABLE 537 GCC COUNTRIES: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 398 TABLE 538 GCC COUNTRIES: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 398 TABLE 539 GCC COUNTRIES: NUCLEIC ACID ISOLATION AND PURIFICATION INSTRUMENTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 399 TABLE 540 GCC COUNTRIES: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET, BY METHOD, 2024–2031 (USD MILLION) 399 TABLE 541 GCC COUNTRIES: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET, BY TYPE, 2024–2031 (USD MILLION) 400 TABLE 542 GCC COUNTRIES: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET, BY SAMPLE TYPE, 2024–2031 (USD MILLION) 400 TABLE 543 GCC COUNTRIES: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR CELLULAR SAMPLES, BY TYPE, 2024–2031 (USD MILLION) 401 TABLE 544 GCC COUNTRIES: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR PRESERVED TISSUE SAMPLES, BY TYPE, 2024–2031 (USD MILLION) 401 TABLE 545 GCC COUNTRIES: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR CELL-FREE SAMPLES, BY TYPE, 2024–2031 (USD MILLION) 401 TABLE 546 GCC COUNTRIES: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 402 TABLE 547 GCC COUNTRIES: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET, BY END USER, 2024–2031 (USD MILLION) 402 TABLE 548 SAUDI ARABIA: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 403 TABLE 549 SAUDI ARABIA: NUCLEIC ACID ISOLATION AND PURIFICATION INSTRUMENTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 403 TABLE 550 SAUDI ARABIA: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET, BY METHOD, 2024–2031 (USD MILLION) 404 TABLE 551 SAUDI ARABIA: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET, BY TYPE, 2024–2031 (USD MILLION) 404 TABLE 552 SAUDI ARABIA: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET, BY SAMPLE TYPE, 2024–2031 (USD MILLION) 405 TABLE 553 SAUDI ARABIA: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR CELLULAR SAMPLES, BY TYPE, 2024–2031 (USD MILLION) 405 TABLE 554 SAUDI ARABIA: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR PRESERVED TISSUE SAMPLES, BY TYPE, 2024–2031 (USD MILLION) 405 TABLE 555 SAUDI ARABIA: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR CELL-FREE SAMPLES, BY TYPE, 2024–2031 (USD MILLION) 406 TABLE 556 SAUDI ARABIA: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 406 TABLE 557 SAUDI ARABIA: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET, BY END USER, 2024–2031 (USD MILLION) 407 TABLE 558 UAE: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 408 TABLE 559 UAE: NUCLEIC ACID ISOLATION AND PURIFICATION INSTRUMENTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 408 TABLE 560 UAE: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET, BY METHOD, 2024–2031 (USD MILLION) 408 TABLE 561 UAE: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET, BY TYPE, 2024–2031 (USD MILLION) 409 TABLE 562 UAE: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET, BY SAMPLE TYPE, 2024–2031 (USD MILLION) 409 TABLE 563 UAE: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR CELLULAR SAMPLES, BY TYPE, 2024–2031 (USD MILLION) 410 TABLE 564 UAE: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR PRESERVED TISSUE SAMPLES, BY TYPE, 2024–2031 (USD MILLION) 410 TABLE 565 UAE: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR CELL-FREE SAMPLES, BY TYPE, 2024–2031 (USD MILLION) 410 TABLE 566 UAE: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 411 TABLE 567 UAE: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET, BY END USER, 2024–2031 (USD MILLION) 411 TABLE 568 REST OF GCC COUNTRIES: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 412 TABLE 569 REST OF GCC COUNTRIES: NUCLEIC ACID ISOLATION AND PURIFICATION INSTRUMENTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 412 TABLE 570 REST OF GCC COUNTRIES: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET, BY METHOD, 2024–2031 (USD MILLION) 412 TABLE 571 REST OF GCC COUNTRIES: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET, BY TYPE, 2024–2031 (USD MILLION) 413 TABLE 572 REST OF GCC COUNTRIES: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET, BY SAMPLE TYPE, 2024–2031 (USD MILLION) 413 TABLE 573 REST OF GCC COUNTRIES: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR CELLULAR SAMPLES, BY TYPE, 2024–2031 (USD MILLION) 414 TABLE 574 REST OF GCC COUNTRIES: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR PRESERVED TISSUE SAMPLES, BY TYPE, 2024–2031 (USD MILLION) 414 TABLE 575 REST OF GCC COUNTRIES: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR CELL-FREE SAMPLES, BY TYPE, 2024–2031 (USD MILLION) 414 TABLE 576 REST OF GCC COUNTRIES: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 415 TABLE 577 REST OF GCC COUNTRIES: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET, BY END USER, 2024–2031 (USD MILLION) 415 TABLE 578 REST OF MIDDLE EAST: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 416 TABLE 579 REST OF MIDDLE EAST: NUCLEIC ACID ISOLATION AND PURIFICATION INSTRUMENTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 416 TABLE 580 REST OF MIDDLE EAST: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET, BY METHOD, 2024–2031 (USD MILLION) 417 TABLE 581 REST OF MIDDLE EAST: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET, BY TYPE, 2024–2031 (USD MILLION) 417 TABLE 582 REST OF MIDDLE EAST: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET, BY SAMPLE TYPE, 2024–2031 (USD MILLION) 418 TABLE 583 REST OF MIDDLE EAST: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR CELLULAR SAMPLES, BY TYPE, 2024–2031 (USD MILLION) 418 TABLE 584 REST OF MIDDLE EAST: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR PRESERVED TISSUE SAMPLES, BY TYPE, 2024–2031 (USD MILLION) 419 TABLE 585 REST OF MIDDLE EAST: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR CELL-FREE SAMPLES, BY TYPE, 2024–2031 (USD MILLION) 419 TABLE 586 REST OF MIDDLE EAST: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 420   TABLE 587 REST OF MIDDLE EAST: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET, BY END USER, 2024–2031 (USD MILLION) 420 TABLE 588 AFRICA: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 421 TABLE 589 AFRICA: NUCLEIC ACID ISOLATION AND PURIFICATION INSTRUMENTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 422 TABLE 590 AFRICA: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET, BY METHOD, 2024–2031 (USD MILLION) 422 TABLE 591 AFRICA: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET, BY TYPE, 2024–2031 (USD MILLION) 423 TABLE 592 AFRICA: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET, BY SAMPLE TYPE, 2024–2031 (USD MILLION) 423 TABLE 593 AFRICA: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR CELLULAR SAMPLES, BY TYPE, 2024–2031 (USD MILLION) 424 TABLE 594 AFRICA: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR PRESERVED TISSUE SAMPLES, BY TYPE, 2024–2031 (USD MILLION) 424 TABLE 595 AFRICA: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR CELL-FREE SAMPLES, BY TYPE, 2024–2031 (USD MILLION) 424 TABLE 596 AFRICA: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 425 TABLE 597 AFRICA: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET, BY END USER, 2024–2031 (USD MILLION) 425 TABLE 598 STRATEGIES ADOPTED BY KEY PLAYERS IN NUCLEIC ACID ISOLATION AND PURIFICATION MARKET, 2023−2026 426 TABLE 599 NUCLEIC ACID ISOLATION AND PURIFICATION MARKET: DEGREE OF COMPETITION 430 TABLE 600 NUCLEIC ACID ISOLATION AND PURIFICATION MARKET: REGION FOOTPRINT 434 TABLE 601 NUCLEIC ACID ISOLATION AND PURIFICATION MARKET: PRODUCT FOOTPRINT 435 TABLE 602 NUCLEIC ACID ISOLATION AND PURIFICATION MARKET: METHOD FOOTPRINT 436 TABLE 603 NUCLEIC ACID ISOLATION AND PURIFICATION MARKET: APPLICATION FOOTPRINT 437 TABLE 604 NUCLEIC ACID ISOLATION AND PURIFICATION MARKET: KEY STARTUPS/SMES 440 TABLE 605 NUCLEIC ACID ISOLATION AND PURIFICATION MARKET: COMPETITIVE BENCHMARKING OF KEY STARTUPS/SMES 441 TABLE 606 NUCLEIC ACID ISOLATION AND PURIFICATION MARKET: PRODUCT LAUNCHES, JANUARY 2023–APRIL 2026 444 TABLE 607 NUCLEIC ACID ISOLATION AND PURIFICATION MARKET: DEALS, JANUARY 2023– APRIL 2026 445 TABLE 608 THERMO FISHER SCIENTIFIC INC.: COMPANY OVERVIEW 447 TABLE 609 THERMO FISHER SCIENTIFIC INC.: PRODUCTS OFFERED 448 TABLE 610 THERMO FISHER SCIENTIFIC INC.: PRODUCT LAUNCHES, JANUARY 2023–APRIL 2026 450 TABLE 611 THERMO FISHER SCIENTIFIC INC.: EXPANSIONS, JANUARY 2023–APRIL 2026 450 TABLE 612 THERMO FISHER SCIENTIFIC INC.: OTHER DEVELOPMENTS, JANUARY 2023–APRIL 2026 451 TABLE 613 QIAGEN N.V.: COMPANY OVERVIEW 452 TABLE 614 QIAGEN N.V.: PRODUCTS OFFERED 453 TABLE 615 QIAGEN N.V.: PRODUCT LAUNCHES, JANUARY 2023–APRIL 2026 454 TABLE 616 QIAGEN N.V.: DEALS, JANUARY 2023–APRIL 2026 455 TABLE 617 MERCK KGAA: COMPANY OVERVIEW 456   TABLE 618 MERCK KGAA: PRODUCTS OFFERED 457 TABLE 619 MERCK KGAA: PRODUCT LAUNCHES, JANUARY 2023–APRIL 2026 461 TABLE 620 F. HOFFMANN-LA ROCHE LTD.: COMPANY OVERVIEW 463 TABLE 621 F. HOFFMANN-LA ROCHE LTD.: PRODUCTS OFFERED 464 TABLE 622 F. HOFFMANN-LA ROCHE LTD.: OTHER DEVELOPMENTS, JANUARY 2023–APRIL 2026 467 TABLE 623 DANAHER CORPORATION: COMPANY OVERVIEW 468 TABLE 624 DANAHER CORPORATION: PRODUCTS OFFERED 469 TABLE 625 DANAHER CORPORATION: DEALS, JANUARY 2023–APRIL 2026 472 TABLE 626 PROMEGA CORPORATION: COMPANY OVERVIEW 474 TABLE 627 PROMEGA CORPORATION: PRODUCTS OFFERED 474 TABLE 628 PROMEGA CORPORATION: DEALS, JANUARY 2023–APRIL 2026 477 TABLE 629 AGILENT TECHNOLOGIES, INC.: COMPANY OVERVIEW 478 TABLE 630 AGILENT TECHNOLOGIES, INC.: PRODUCTS OFFERED 479 TABLE 631 AGILENT TECHNOLOGIES, INC.: OTHER DEVELOPMENTS, JANUARY 2023–APRIL 2026 480 TABLE 632 BIO-RAD LABORATORIES, INC.: COMPANY OVERVIEW 481 TABLE 633 BIO-RAD LABORATORIES, INC.: PRODUCTS OFFERED 483 TABLE 634 ILLUMINA, INC.: COMPANY OVERVIEW 484 TABLE 635 ILLUMINA, INC.: PRODUCTS OFFERED 485 TABLE 636 ILLUMINA, INC.: PRODUCT LAUNCHES, JANUARY 2023–APRIL 2026 486 TABLE 637 TAKARA BIO INC.: COMPANY OVERVIEW 487 TABLE 638 TAKARA BIO INC.: PRODUCTS OFFERED 488 TABLE 639 NEW ENGLAND BIOLABS: COMPANY OVERVIEW 492 TABLE 640 NEW ENGLAND BIOLABS: PRODUCTS OFFERED 492 TABLE 641 NEW ENGLAND BIOLABS: PRODUCT LAUNCHES, JANUARY 2023–MARCH 2026 495 TABLE 642 A&A BIOTECHNOLOGY: COMPANY OVERVIEW 496 TABLE 643 A&A BIOTECHNOLOGY: PRODUCTS OFFERED 497 TABLE 644 REVVITY INC.: COMPANY OVERVIEW 498 TABLE 645 REVVITY INC.: PRODUCTS OFFERED 500 TABLE 646 BIONEER CORPORATION: COMPANY OVERVIEW 501 TABLE 647 BIONEER CORPORATION: PRODUCTS OFFERED 502 TABLE 648 HIMEDIA LABORATORIES PRIVATE LIMITED: COMPANY OVERVIEW 503 TABLE 649 HIMEDIA LABORATORIES PRIVATE LIMITED: PRODUCTS OFFERED 503 TABLE 650 KILPEST INDIA LIMITED: COMPANY OVERVIEW 504 TABLE 651 APICAL SCIENTIFIC SDN. BHD.: COMPANY OVERVIEW 505 TABLE 652 ENDRESS+HAUSER GROUP SERVICES AG: COMPANY OVERVIEW 506 TABLE 653 GENAXXON BIOSCIENCE GMBH: COMPANY OVERVIEW 507 TABLE 654 LGC BIOSEARCH TECHNOLOGIES: COMPANY OVERVIEW 508 TABLE 655 ZYMO RESEARCH CORPORATION: COMPANY OVERVIEW 509 TABLE 656 NORGEN BIOTEK CORP.: COMPANY OVERVIEW 512 TABLE 657 OMEGA BIO-TEK, INC.: COMPANY OVERVIEW 513 TABLE 658 FAVORGEN BIOTECH CORPORATION: COMPANY OVERVIEW 515 TABLE 659 TIANGEN BIOTECH(BEIJING)CO., LTD.: COMPANY OVERVIEW 516 TABLE 660 AUTOGEN INC.: COMPANY OVERVIEW 517 TABLE 661 PCR BIOSYSTEMS: COMPANY OVERVIEW 518 TABLE 662 BIOGENUIX: COMPANY OVERVIEW 519 TABLE 663 MP BIOMEDICALS: COMPANY OVERVIEW 520 TABLE 664 NANJING VAZYME BIOTECH CO., LTD.: COMPANY OVERVIEW 521 TABLE 665 IMPACT ANALYSIS OF SUPPLY-SIDE AND DEMAND-SIDE FACTORS 532 TABLE 666 NUCLEIC ACID ISOLATION AND PURIFICATION MARKET: RISK ANALYSIS 535 FIGURE 1 NUCLEIC ACID ISOLATION AND PURIFICATION MARKET SEGMENTATION & REGIONAL SCOPE 46 FIGURE 2 NUCLEIC ACID ISOLATION AND PURIFICATION MARKET: YEARS CONSIDERED 48 FIGURE 3 MARKET SCENARIO 51 FIGURE 4 GLOBAL NUCLEIC ACID ISOLATION AND PURIFICATION MARKET, 2024–2031 52 FIGURE 5 MAJOR STRATEGIES ADOPTED BY KEY PLAYERS IN NUCLEIC ACID ISOLATION AND PURIFICATION MARKET, 2023–2026 53 FIGURE 6 DISRUPTIONS INFLUENCING GROWTH OF NUCLEIC ACID ISOLATION AND PURIFICATION MARKET 54 FIGURE 7 HIGH-GROWTH SEGMENTS IN NUCLEIC ACID ISOLATION AND PURIFICATION MARKET, 2026–2031 55 FIGURE 8 ASIA PACIFIC TO REGISTER HIGHEST CAGR IN NUCLEIC ACID ISOLATION AND PURIFICATION MARKET, IN TERMS OF VALUE, DURING FORECAST PERIOD 56 FIGURE 9 ADVANCEMENTS IN NUCLEIC ACID ISOLATION AND PURIFICATION PLATFORMS TO DRIVE MARKET GROWTH 58 FIGURE 10 KITS ACCOUNTED FOR LARGEST SHARE OF NUCLEIC ACID ISOLATION AND PURIFICATION MARKET IN NORTH AMERICA IN 2025 59 FIGURE 11 ASIA PACIFIC IS LIKELY TO BE FASTEST-GROWING MARKET IN GLOBAL NUCLEIC ACID ISOLATION AND PURIFICATION MARKET DURING FORECAST PERIOD 60 FIGURE 12 HOSPITALS & DIAGNOSTIC CENTERS TO DOMINATE MARKET DURING FORECAST PERIOD 61 FIGURE 13 NUCLEIC ACID ISOLATION AND PURIFICATION MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 62 FIGURE 14 NUCLEIC ACID ISOLATION AND PURIFICATION MARKET: PORTER'S FIVE FORCES ANALYSIS 73 FIGURE 15 NUCLEIC ACID ISOLATION AND PURIFICATION MARKET: VALUE CHAIN ANALYSIS 79 FIGURE 16 NUCLEIC ACID ISOLATION AND PURIFICATION MARKET: SUPPLY CHAIN ANALYSIS 81 FIGURE 17 NUCLEIC ACID ISOLATION AND PURIFICATION MARKET: ECOSYSTEM ANALYSIS 82 FIGURE 18 INDICATIVE SELLING PRICE OF NAIP PRODUCTS, BY TYPE, 2025 86 FIGURE 19 NUCLEIC ACID ISOLATION AND PURIFICATION MARKET: TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 89 FIGURE 20 VC/PRIVATE EQUITY INVESTMENT TRENDS & STARTUP LANDSCAPE 89 FIGURE 21 TOP APPLICANTS/OWNERS (COMPANIES) FOR NUCLEIC ACID ISOLATION AND PURIFICATION PRODUCTS/TECHNOLOGY PATENTS, 2015–2025 102 FIGURE 22 IMPACT OF AI/GEN AI ON NUCLEIC ACID ISOLATION AND PURIFICATION MARKET 105 FIGURE 23 CANADA: REGULATORY PROCESS FOR MEDICAL DEVICES 114 FIGURE 24 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY PRODUCT 123 FIGURE 25 KEY BUYING CRITERIA, BY END USER 124 FIGURE 26 NORTH AMERICA: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET SNAPSHOT 289 FIGURE 27 ASIA PACIFIC: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET SNAPSHOT 341 FIGURE 28 REVENUE ANALYSIS OF KEY PLAYERS IN NUCLEIC ACID ISOLATION AND PURIFICATION MARKET, 2021–2025 (USD MILLION) 428 FIGURE 29 MARKET SHARE ANALYSIS OF KEY PLAYERS IN NUCLEIC ACID ISOLATION AND PURIFICATION MARKET (2025) 430 FIGURE 30 NUCLEIC ACID ISOLATION AND PURIFICATION MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2025 432 FIGURE 31 NUCLEIC ACID ISOLATION AND PURIFICATION MARKET: COMPANY FOOTPRINT 433 FIGURE 32 NUCLEIC ACID ISOLATION AND PURIFICATION MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2025 439 FIGURE 33 EV/EBITDA OF KEY VENDORS 442 FIGURE 34 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS 442 FIGURE 35 BRAND/PRODUCT COMPARATIVE ANALYSIS, BY PRODUCT 443 FIGURE 36 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2025) 448 FIGURE 37 QIAGEN N.V.: COMPANY SNAPSHOT (2025) 453 FIGURE 38 MERCK KGAA: COMPANY SNAPSHOT (2025) 457 FIGURE 39 F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT (2025) 464 FIGURE 40 DANAHER CORPORATION: COMPANY SNAPSHOT (2025) 469 FIGURE 41 AGILENT TECHNOLOGIES, INC.: COMPANY SNAPSHOT (2025) 479 FIGURE 42 BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT (2025) 482 FIGURE 43 ILLUMINA, INC.: COMPANY SNAPSHOT (2025) 485 FIGURE 44 TAKARA BIO INC.: COMPANY SNAPSHOT (2025) 488 FIGURE 45 REVVITY INC.: COMPANY SNAPSHOT (2025) 499 FIGURE 46 BIONEER CORPORATION: COMPANY SNAPSHOT (2025) 502 FIGURE 47 NUCLEIC ACID ISOLATION AND PURIFICATION MARKET: RESEARCH DESIGN 522 FIGURE 48 NUCLEIC ACID ISOLATION AND PURIFICATION MARKET: BREAKDOWN OF PRIMARIES 525 FIGURE 49 NUCLEIC ACID ISOLATION AND PURIFICATION MARKET: INSIGHTS FROM PRIMARIES 526 FIGURE 50 GLOBAL NUCLEIC ACID ISOLATION AND PURIFICATION MARKET ESTIMATION (SUPPLY-SIDE ANALYSIS), 2025 527 FIGURE 51 NUCLEIC ACID ISOLATION AND PURIFICATION MARKET: COMPANY REVENUE ANALYSIS-BASED ESTIMATION (BOTTOM-UP APPROACH) (2025) 527 FIGURE 52 ILLUSTRATIVE EXAMPLE OF THERMO FISHER SCIENTIFIC INC.: REVENUE ANALYSIS (2025) 528 FIGURE 53 SEGMENTAL MARKET SIZE ESTIMATION: TOP-DOWN APPROACH 529 FIGURE 54 NUCLEIC ACID ISOLATION AND PURIFICATION MARKET: CAGR PROJECTIONS 531 FIGURE 55 NUCLEIC ACID ISOLATION AND PURIFICATION MARKET: DATA TRIANGULATION 533

同分類最新報告（醫療與生命科學）

查看醫療與生命科學全部報告 →

量子訊息有限公司為 MarketsandMarkets 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們